Epigenetic reprogramming of myeloid-derived suppressor cells sensitizes breast and pancreatic cancers to immune checkpoint inhibition by Christmas, Brian James
 
EPIGENETIC REPROGRAMMING OF MYELOID-DERIVED 
SUPPRESSOR CELLS SENSITIZES BREAST AND PANCREATIC 













A dissertation submitted to Johns Hopkins University in conformity with the 








A B S T R A C T 
Immune checkpoint inhibition (ICI) has revolutionized treatment in cancers that 
are naturally immunogenic by enabling infiltration of T cells into the tumor 
microenvironment (TME) and promoting cytotoxic signaling pathways. Tumors 
possessing complex immunosuppressive TME’s such as breast and pancreatic cancers 
present unique therapeutic obstacles as response rates to ICI remain low. Such tumors 
often recruit myeloid-derived suppressor cells (MDSCs) whose functioning prohibits 
both T-cell activation and infiltration. 
 We show that combining the histone deacetylase inhibitor entinostat (ENT) with 
the ICIs, anti-PD-1 and anti-CTLA-4, significantly improve survival in murine models of 
breast and pancreatic cancer. We show this improved survival is correlated with  
decreased granulocytic-MDSC (G-MDSC) immunosuppressive capabilities of 
intratumoral G-MDSCs in both models via flow cytometry and ex vivo functional assays. 
Additionally, we show that combination therapy increases the infiltration of activated 
cytotoxic T cells in the TME in both models. We also perform genetic profiling on both 
isolated intratumoral G-MDSCs as well as whole TIL and found significant changes in 
immune-related pathways. Specifically, intratumoral G-MDSCs from treated animals 
showed changes in various signaling pathways that converge at STAT3, a known 
transcription factor that drives MDSC function. We confirmed a decrease in STAT3 
phosphorylation in treated G-MDSCs, which suggested ENT may be reprogramming 
MDSC function via STAT3. We next validated the MDSC-like cell line J774M for future 
mechanistic studies aimed to detail changes in STAT3 binding activity. We found J774M 
cells phenotypically and functionally resemble intratumoral MDSCs via flow cytometry 
in addition to arginase production and T cell proliferation assays. We also show ENT 
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inhibits these immunosuppressive qualities of the J774M line, which is correlated with a 
decrease in STAT3 phosphorylation. Taken together, these data show that ENT is able to 
sensitize non-immunogenic breast and pancreatic cancers to ICI therapy by 
reprogramming intratumoral MDSCs potentially via changes in STAT3 activity. 
Additionally, the validation of the J774M line demonstrates it is a reasonable model for 
MDSC suppression and ENT-induced MDSC dysfunction.
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I N T R O D U C T I O N 
 
ICIs induce immune responses to tumors by releasing the brakes on effector T 
cells that naturally infiltrate the TME. As a result, non-immunogenic cancers with low 
intrinsic T cell infiltration, such as breast and pancreas cancers, often have low response 
rates to ICI therapy (1–9). The natural resistance of breast and pancreatic tumors to single 
agent ICI therapy is in part due to a lack of infiltrating T cells as well as to expression of 
various immunosuppressive signals on suppressive immune cells and the tumor that limit 
T cell infiltration and activation by these therapies. The monocyte component of both 
breast and pancreatic TMEs play a major role in the suppression of tumor-specific 
responses, as these tumors are often infiltrated by several immunosuppressive monocytic 
cell types, including M2-like TAMs and MDSCs (10), and these in turn inhibit 
infiltration and activity of CD8+ T cells with the potential to kill tumors (11–13).  
Two subtypes of MDSCs, granulocytic (G-MDSCs) and monocytic-MDSCs (M-
MDSCs), collectively inhibit T cell functionality by depleting L-arginine through 
arginase-1 (Arg-1) expression, and by inducing nitric oxide synthase (iNOS) expression, 
PD-L1 expression, TGF-b production, and regulatory T cells (Tregs) (14–20). While 
typically less abundant in the TME, M-MDSCs are considered to be significantly more 
immunosuppressive than G-MDSCs (21). As with many myeloid sub-types, M-MDSCs 
are a fluid population that can quickly differentiate into immunosuppressive TAMs 
within the TME (22). Despite being less immunosuppressive than M-MDSCs, G-MDSCs 
are the predominant MDSC subtype in most tumors and primarily inhibit T cell function 
by producing both reactive oxidative species and NO, which results in the down-
regulation of T cell receptors (TCRs) on the surface of effector T cells and subsequent 
inhibition of TCR signaling (21,23).  STAT3 acts as a major driver of many of these 
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immunosuppressive functions of MDSCs in addition to inducing MDSC proliferation 
(21,24). Studies highlighting the importance of STAT3 in MDSC biology have that 
STAT3 activity is essential for MDSC induction (25,26) and ablation of STAT3 activity 
renders MDSCs dysfunctional (27,28). High numbers of tumor infiltrating myeloid cells 
have been correlated with early or local metastatic relapse (29). Previous studies have 
also shown changes in both circulating and tumor infiltrating G-MDSCs in response to 
ICIs as a potential mechanism inhibiting anti-tumor responses (21,29,30). Thus, strategic 
reprogramming of these myeloid responses may overcome the immunosuppressive 
microenvironment and lead to enhanced response to immune therapy through improved T 
cell infiltration and function.  
Recent studies using epigenetic modulatory drugs have shown promise in 
decreasing the infiltration and inhibitory capabilities of immunosuppressive cells. The 
histone deacteylase inhibitor (HDACi) entinostat (ENT) has been shown to decrease the 
number of inhibitory Tregs within the TME when combined with IL-2 therapy or a 
survivin-based vaccine. This reduction in Tregs correlated with reduced tumor burden 
(31). HDACi’s were also shown to ablate the immunosuppressive ability of MDSCs 
when combined with ICIs in in vivo models of lung and renal cell cancer (30). As further 
evidence, Kim and colleagues also showed similar results in highly aggressive triple 
negative breast and colon cancer models, where co-treatment with ENT and ICIs resulted 
in eradication of metastases and decreased MDSCs in circulation and within tumors (29). 
Finally, Tomita et al. reported decreased circulating G-MDSCs and M-MDSCs in clinical 
samples of breast cancer patients treated with ENT alone (32). Taken together, these data 
suggest that ENT can alter suppressive myeloid populations in multiple tumor types and 
collaborate with immunotherapies to slow tumor growth and progression.  
 3 
Our work explored the impact of HDACi’s on the HER2+ breast and PDAC TME 
in immunocompetent murine models. Combination therapy of ENT with anti-PD-1 or 
anti-CTLA-4 significantly improves survival as compared to either agent alone or 
combined ICIs. To our surprise, the class I HDACi ENT increased infiltration of G-
MDSCs into the tumor but interestingly, changed the polarity of their immunosuppressive 
ability to a non-functional phenotype.  Flow cytometry and gene expression profiling of 
treated tumors demonstrated changes in expression of functional molecules and pathways 
involved in proliferation and motility. These observations suggest ENT decreased the 
immunosuppressive nature of infiltrating MDSCs and allowed for ICIs to increase the 
infiltration and cytotoxicity of T cells by altering STAT3 activity in MDSCs. We pursued 
this hypothesis in the  MDSC-like cell line J774M and showed J774M cells treated with 
ENT were unable to produce Arg-1 and suppress T cell proliferation, which correlated 
with a decrease in STAT3 phosphorylation. Taken together, these data further support 
that ENT reprograms MDSCs by altering STAT3 activity. 
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Efficacy of ICI therapy is often ineffective in-immunogenic tumors, such as breast 
and pancreatic cancers. We attempted to sensitize non-immunogenic breast and 
pancreatic tumors to ICI using epigenetic modulation to target MDSC trafficking and 
function in order to foster a less immunosuppressive TME. We showed that combining a 
histone deacetylase inhibitor, ENT, with anti–PD-1, anti–CTLA-4, or both, significantly 
improved tumor-free survival in both the HER2/neu transgenic breast cancer and the 
Panc02 metastatic pancreatic cancer mouse models. Using flow cytometry, gene 
expression profiling, and ex vivo functional assays, we characterized populations of 
tumor-infiltrating lymphocytes (TILs) and MDSCs, as well as their functional 
capabilities. We showed that addition of ENT to checkpoint inhibition led to significantly 
decreased suppression by granulocytic-MDSCs in the TME of both tumor types. We also 
demonstrated an increase in activated granzyme-B–producing CD8+ T effector cells in 
mice treated with combination therapy. Gene expression profiling of both MDSCs and 
TILs identified significant changes in immune-related pathways. In summary, addition of 
ENT to ICI significantly altered infiltration and function of innate immune cells, allowing 
for a more robust adaptive immune response. These findings provide a rationale for 





 Immunotherapy has changed the standard of care for some patients with advanced 
cancers and has great promise to prevent recurrence and prolong survival due to the long-
term memory capabilities of the adaptive immune system. Although the presence of 
tumor-infiltrating lymphocytes (TILs) and evidence of immune activation have been 
associated with improved outcomes in HER2+ and triple-negative breast cancers (TNBC) 
(33,34), only modest response rates have been observed with use of single-agent immune 
checkpoint inhibitors (ICIs) (1–7,35). Preclinical studies have focused on understanding 
these therapies in TNBC models (29) but have yet to thoroughly examine other subtypes 
of breast cancer. It has also been previously reported that antibodies blocking 
programmed cell death protein-1 (anti–PD-1) can significantly improve the activity of 
anti-HER2 therapies, but we have yet to understand if there is any added benefit of other 
ICIs (36). Similarly, single-agent ICIs have been shown to be ineffective in the clinical 
setting in metastatic pancreatic ductal adenocarcinomas (PDAC) (8,9). However, efficacy 
has been seen using combinatorial approaches in preclinical models. It has been shown 
that priming the tumor with a vaccine sensitizes PDAC to anti–PD-1 therapy by inducing 
the infiltration of cytotoxic CD8+ T cells (15). In PDAC patients, a similar vaccine was 
reported to induce TILs (37). Improved efficacy of both anti–PD-1 and anti–CTLA-4 was 
achieved in murine models of PDAC by reprogramming immunosuppressive tumor-
associated macrophages (TAMs) (16). Taken together, these studies indicate the 
possibility to sensitize traditionally non-immunogenic tumors to ICI therapy if TILs can 
be recruited and induced and/or immunosuppressive factors reduced within the tumor 
microenvironment (TME). 
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The natural resistance of breast and pancreatic tumors to single-agent ICI therapy 
is due to a lack of infiltrating T cells and an abundance of suppressive immune cells such 
as MDSCs. Specifically, granulocytic (G-MDSCs) and monocytic MDSCs (M-MDSCs) 
collectively inhibit T-cell function by depleting L-arginine through arginase-1 (Arg-1) 
expression and by inducing PD-L1 expression and the recruitment of regulatory T cells 
(Tregs) (14,15,19,20). High numbers of tumor-infiltrating myeloid cells correlates with 
early or local metastatic relapse (29). Previous studies have also shown changes in both 
circulating and tumor-infiltrating G-MDSCs in response to ICIs as a potential mechanism 
inhibiting antitumor responses (21,29,30). Thus, targeting and strategic reprogramming 
of these myeloid responses may overcome the immunosuppressive microenvironment 
and lead to an enhanced response to immune therapy through improved T-cell infiltration 
and function.  
Studies using epigenetic modulatory drugs have shown promise in decreasing the 
infiltration and inhibitory capabilities of immunosuppressive cells. ENT ablates MDSC-
mediated immunosuppressive activity when combined with ICIs in in vivo models of lung 
and renal cell cancer (30). Tomita et al. reported decreased circulating G-MDSCs and M-
MDSCs in clinical samples of breast cancer patients treated with ENT in combination 
with an aromatase inhibitor compared to placebo combined with aromatase inhibitor (32). 
Taken together, these data suggest that ENT can alter suppressive myeloid populations in 
multiple tumor types and synergize with immunotherapies to slow tumor growth and 
progression.  
Our work explored the impact of ENT on the HER2+ breast and PDAC TMEs in 
immunocompetent mice. Combination therapy of ENT with anti–PD-1 or anti–CTLA-4 
significantly improved survival compared to either agent alone or combined ICIs. ENT 
 7 
increased tumor infiltration by G-MDSCs and changed the polarity of their 
immunosuppressive ability to a nonfunctional phenotype. Flow cytometry and gene 
expression profiling of treated tumors demonstrated altered expression of functional 
molecules and specific genetic pathways involved in proliferation and motility. Our 
observations suggest that G-MDSCs can exhibit multiple phenotypes and support that a 
possible mechanism by which ENT allows ICIs to augment the infiltration and 
cytotoxicity of cancer-killing T cells is through the ablation of the immunosuppressive 
function of these infiltrating myeloid cells. 
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Materials and Methods 
Mice and cell lines 
All animal studies were approved by Institutional Review Board of Johns Hopkins 
University. Animals were kept in pathogen-free conditions and were treated in 
accordance with institutional and American Association of Laboratory Animal 
Committee policies. The neu-N mice were originally from W. Muller McMaster 
University, Hamilton, Ontario, Canada. Colonies were renewed yearly from Jackson labs 
and bred in house by brother/sister mating. For studies of metastatic pancreatic cancer, 
we used male C57BL/6J (The Jackson Laboratories, stock #000664) mice. The T cell 
receptor (TCR) transgenic mice are specific for the immunodominant HER2/neu epitope 
neu420-429 and were made in house at the JHU Transgenic Core Laboratory as previously 
described (38). These mice were bred in house by brother/sister mating, and each animal 
was assessed for expression of the desired neu-specifc Vb region via staining with the H-
2Dq rat HER2/neu420-429 PDSLRDLSVF tetramer (NIH Tetramer Core Facility).  
All cell lines were regularly tested for Mycoplasma every three months in accordance to 
laboratory policy. NT2.5 cells were derived from spontaneous mammary tumors growing 
in female neu-N mice. In vitro cell lines were established and authenticated as previously 
described (39,40). Culture conditions for NT2.5 cells were as follows: 37°C, 5% CO2 in 
RPMI 1640 (Gibco, cat. 11875-093) supplemented with 20% fetal bovine serum (Gemini, 
cat. 100-106), 1.2% HEPES buffer (Gibco, cat. 15630-080), 1% L-glutamine (Gibco, cat. 
25030-081), 1% MEM non-essential amino acids (Gibco, cat. 11140-050), 0.5% 
penicillin streptomycin (Gibco, cat. 15140-122), 1% sodium pyruvate (Sigma, cat. 
S8636), 0.2% insulin (NovoLog, cat. U-100), 0.02% gentamicin (Sigma, cat. G1397). 
Panc02 is a murine pancreatic tumor cell line with ductal morphology derived from a 
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methylcholanthrene-treated C57B1/6 mouse and authenticated as previously described 
(41,42). Culture conditions for Panc02 cells were as follows: 37°C, 10% CO2 in DMEM 
(Gibco, cat. 11965-084) supplemented with 10% fetal bovine serum (Gemini, cat. 100-
106), 1% L-glutamine (Gibco, cat. 25030-081), 0.5% penicillin streptomycin (Gibco, cat. 
15140-122). The T2Dq cells are a fibroblast cell line established via transfection with 
murine H-2Dq as previously described (43). Culture conditions for T2Dq cells are as 
follows: 37°C, 5% CO2 in RPMI supplemented with 10% fetal bovine serum (Gibco, cat. 
100-106), 1% L-glutamine (Gibco, cat. 25030-081), 1% sodium pyruvate (Gibco, cat. 
11965-084), 1% MEM non-essential amino acids (Gibco, cat. 11140-050), 0.5% 
penicillin streptomycin (Gibco, cat. 15140-122), 0.0007% Hygromycin B (Roche, cat. 
10843555001). T2Dq cells were cultured from frozen stocks and passaged three times 
before use.  
 
Neu-N in vivo studies 
The neu-N model is a syngeneic model whereby NT2.5 cells that were derived from a 
spontaneous mammary tumor are implanted via injection of 5 x 104 cells into the 
mammary fat pad of 7-8 week old female neu-N mice (39). NT2.5 cells were cultured 
from frozen stocks and passaged twice before injection. Tumors were allowed to seed for 
3 days prior to initiating treatment with various drug combinations as described below. 
Untreated mice developed palpable tumors within 1 week. 
 
PDAC hemi-splenectomy in vivo studies 
To study metastatic PDAC, we used a hemi-splenectomy model using 7-8 week old 
syngeneic male C57BL/6J. This involved giving an intrasplenic injection of 2x106 of the 
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pancreatic adenocarcinoma cell line (Panc02), as previously described (44–46). Panc02 
cells were cultured from frozen stocks and passaged twice before injection. Metastases 
were allowed to establish for 7 days prior to starting treatment with various drug 
combinations as described below. 
 
Rationale for mouse model selection 
We selected the Panc02 hemi-splenectomy model in order to recapitulate late stage, 
metastatic disease, as this is most commonly how patients present. It should be noted that 
the Panc02 cell line was derived from a chemically induced tumor and contains a high 
mutational burden. Other groups circumvent this issue by using the genetically 
engineered KPC PDAC model, which results in pancreatic tumors that are more 
genetically and pathologically similar human PDAC (45,47,48). While the KPC model 
more accurately recapitulates primary disease in humans, these animals take a minimum 
16 weeks to develop locally invasive PDAC and develop salivary tumors before 
metastases occur. These tumors grow large and often prohibit maintenance of mice long 
enough to study natural metastases (45). We recognize the shortcomings of using the 
Panc02 cell line, which is why we paired the findings in this model with those in an 
extremely tolerant and non-immunogenic breast cancer model (46). Future work with the 
KPC model could yield informative data to further translate the outcomes from 
preclinical models to human disease. 
 
Drug dosing and selection 
The ENT dosing solution (5 mg/kg) was made by suspending solid ENT (generously 
provided by Syndax Pharmaceuticals) in 0.5% methylcellulose via sonication and given 
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by oral gavage daily for three weeks as described in Fig. 1a. To imitate oral gavage in 
control groups, 0.5% methylcellulose was given to vehicle mice as well as mice receiving 
only antibody therapy during the three weeks of ENT dosing. Mice received anti-PD-1 
and/or anti-CTLA-4 twice a week for three weeks as stated in Fig. 1a. All studies in neu-
N model were performed with and without an anti-HER2 antibody to mimic treatment 
with and without trastuzumab. Anti-HER2 antibody was given once a week for three 
weeks as described in Fig. 1a. Following initial three weeks of treatment, as described 
above, maintenance dosing was continued with antibodies every other week. During 
maintenance therapy, animals receive two doses of anti-PD-1 and/or anti-CTLA-4 as well 
as one dose of anti-HER2 every other week as shown in Fig. 1a. Dosage of antibodies 
was as follows: anti–PD-1, 100 µg/mouse via intraperitoneal injection (i.p.); anti–CTLA-
4, 100 µg/mouse i.p.; anti-HER2, 100 µg/mouse i.p. Monoclonal antibodies were 
obtained from BioXcell [anti–PD-1 (clone RPM1-14), anti–CTLA-4 (clone 9H-10), and 
anti-HER2 (clone 7.16.4)] and all were diluted to 0.5 mg/mL in PBS. Isotypes were used 
to treat vehicle mice and were also obtained from BioXcell [anti–PD-1 isotype: rat IgG2a 
(clone 2A3); anti–CTLA-4 isotype: polyclonal Syrian Hamster IgG; anti-HER2 isotype: 
mouse IgG2a (clone C1.18.4)]. All isotype antibodies were also diluted to 0.5 mg/mL in 
PBS. Dosages of each antibody were based off of prior studies (29). For mice receiving 
dual checkpoint antibody therapy, anti–CTLA-4 was given alone twice prior to addition 
of anti–PD-1, given that anti–CTLA-4 has been described as a T-cell repertoire–
expanding agent, whereas anti–PD-1 has been determined to expand antigen-experienced 
T cells and help prevent the exhaustion of activated T cells (49).  
For preliminary experiments using the demethylating agent SGI-110 (Astex) and the 
histone deacetylase inhibitor ACY-1215 (Acetylon), the PDAC hemi-splenectomy 
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described above was used. Murine GVAX was prepared by irradiating a 1:1 mixture of 
Panc02 and the GMCSF-secreting bystander line B78H1 as previously described (42,50). 
A low dose of cyclophosphamide (100 mg/kg) was given four days post-surgery and 
GVAX was administered five days post-surgery sub-cutaneously into three limbs of the 
mice. SGI-110 was administered subcutaneously into the flank of the animal at 24.4 
mg/kg once a week over the course of three weeks while ACY-1215 was administered 
i.p. at 50 mg/kg daily. Following dosing of ACY-1215 and GVAX, survival was 
monitored until 120 days post-surgery.  
 
Rationale for use of entinostat 
It has previously been shown that inhibition of class I HDACs targeted by ENT improves 
TLR signaling and cytokine production in myeloid cells (51) as well as cytokine 
signaling in T cells (52). Therefore, we hypothesized that use of ENT acted on these cell 
types to help sensitive non-immunogenic tumors to ICIs. While we showed that ENT did 
indeed improve efficacy of ICIs in the neu-N and PDAC models, the mechanism 
appeared to be largely dependent on inhibiting the ability of MDSCs to produce 
immunosuppressive factors, specifically arginase-1. Although a specific class I HDAC 
has not been identified as a regulator of Arg-1, a few studies illustrate a potential 
mechanism for the regulation of Arg1 transcription involving HDAC2. It has previously 
been shown that a complex of Tet2 and HDAC2 is required for regulating the 
transcription of various inflammatory genes in macrophages, such as Il6 and Tnfa, and 
this regulation can be abrogated with HDAC2 siRNA as well as entinostat in vitro (53). 
Additionally, Pan et al. showed that myeloid-specific knockout of Tet2 resulted in 
decreased Arg-1 expression in TAMs as well as decreased ability to suppress T cell 
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proliferation (54). Taken together, these studies suggest Arg-1 could be regulated in a 
similar way as IL-6, where Tet2 recruits HDAC2 to the arginase-1 promoter to regulate 
gene transcription.  
Rationale for addition of ICIs to ENT was also provided by two promising ongoing 
clinical trials that combine nivolumab, ipilumumab and ENT (NCT02453620, 
NCT03250273). However, mechanisms of action of these drug combinations remain 
elusive and thus, these preclinical studies were designed to inform rational design of 
clinical correlates for these trials and elucidate mechanisms behind potential anti-tumor 
responses. 
 
Survival and tumor growth assays 
 Following injection of either Panc02 or NT2.5 cells, mice were treated for three 
weeks as depicted in Fig. 1a, and then received maintenance therapy until succumbing to 
disease or requiring sacrifice due to tumor burden (up to 2 cm3). In the neu-N model, 
mice were examined for palpable tumors starting one-week post tumor cell challenge, 
and subsequently measured by calipers (± 0.01 mm) twice weekly. Survival experiments 
were continued until mice were euthanized according to protocol due to tumor burden 
(neu-N model) or the development of ascites (PDAC model).  
 
Tumor dissociation 
 To obtain single-cell suspensions from breast tumors, tumors were harvested, 
weighed, diced, and then dissociated using a tumor dissociation kit (Miltenyi Biotec, cat. 
130-096-730) and the OctoDissociator (Miltenyi Biotec) per the manufacturer’s 
instructions. The 37C_m_TDK_2 program was used to dissociate tumors per the 
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manufacturer’s instructions. Samples were filtered using a 40 µm cell strainer and red 
blood cells were lysed using ACK lysis buffer (Quality Biological, cat. 118-156-721). 
The resulting single-cell suspensions were used for subsequent isolation of specific 
immune cell types or flow cytometry as described below. Blood from neu-N mice was 
obtained via retro-orbital bleeds as per protocol. Red blood cells were lysed using ACK 
lysis buffer (Quality Biological, cat. 118-156-721). Isolated cells were analyzed via flow 
cytometry. To obtain single-cell suspensions of livers containing metastases in the PDAC 
model, livers were harvested and processed by mashing the liver through 100 µm and 40 
µm cell strainers as previously described (50). Red blood cells were lysed using ACK 
lysis buffer (Quality Biological, cat. 118-156-721) and liver pellets were resuspended in 
40% Percoll (GE Healthcare Life Sciences, cat. 17-0891-01) and underlayed with 80% 
Percoll. The immune cell layer was then removed and analyzed via flow cytometry.  
 
Immune cell isolation 
G-MDSCs were isolated from single-cell suspensions from tumors following tumor 
dissociation using Miltenyi Biotec’s Myeloid-Derived Suppressor Cell Isolation Kit (cat. 
130-094-538) according to the manufacturer’s protocol. Ly6G+ cells were positively 
selected to isolate G-MDSCs from Ly6G- M-MDSCs and were passed through LS 
columns (Miltenyi Biotec, cat. 130-042-401) twice to increase purity. Eluted G-MDSCs 
were then used for downstream assays described below. CD8+ neu-specific T cells were 
negatively isolated from spleens of the TCR transgenic mice described above by mashing 
spleens through 100 µm cell strainers. Red blood cells were lysed using ACK lysis buffer 
(Quality Biological, cat. 118-156-721), and CD8+ T cells were isolated from spleen 
pellets using the EasySep Mouse CD8+ Isolation Kit (StemCell, cat. 19853) per the 
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manufacturer’s instructions. CD8+ T cells were then used for the ex vivo suppression 
assay described below. 
 
Flow cytometry  
Isolated single-cell suspensions were washed and then incubated for 30 minutes with 
Live/Dead Near-IR (ThermoFisher, cat. L10119) according to the manufacturer’s 
protocol, followed by a 30-minute incubation with the appropriate flow cytometry 
antibodies (Supplementary Table 1). For samples being analyzed for cytokine expression, 
single-cell suspensions obtained from tumor dissociations were plated at 37°C with anti-
CD3/CD28 beads (ThermoFisher, cat. 11453D) overnight at a bead-to-cell ratio of 1:1 
per the manufacturer’s instructions for T cell activation. A protein transport inhibitor 
cocktail (eBioscience, cat. 00-4980-03) was introduced at 1x concentration during the last 
4-6 hours of stimulation. The samples were harvested after 16 hours. For samples being 
stained for intracellular markers, cells were fixed and permeabilized (Transcription 
Factor Fixation/Permeabilization kit, eBioscience, cat. 00-5523-00) and then incubated 
with the appropriate antibodies for 30 minutes. Samples were run on a CytoFLEX or 
Gallios (Beckman Coulter) cytometer and analyzed using FlowJo (FlowJo LLC) or 
Kaluza (Beckman Coulter).  
 
Flow cytometry gating strategies 
G- and M-MDSCs were identified by gating out debris from bulk tumor based on forward 
scatter and side scatter. Single cells were then gated by forward scatter-area and forward 
scatter-height. Dead cells were then gated out of the bulk tumor cell population. T cells 
and mature macrophages were gated out by selecting the CD3 and F4/80 double negative 
 16 
population, respectively. CD11b+ cells were then gated, and G- and M-MDSCs were 
differentiated using Ly6G vs. Ly6C. G-MDSCs were defined as Ly6G+ Ly6Clo, and M-
MDSCs were defined as Ly6G- Ly6C+. See Supplementary Fig. S1a. Of note, we found 
that staining with CD45 in combination with more specific markers, such as CD3 and 
CD11b, did not further exclude non-immune cell types from the final gated populations 
as compared to single staining with CD3 or CD11b. For example, there were very few 
cells that were positive for CD3 or CD11b and negative for CD45. Given these findings, 
we did not use CD45 in our final FACS panels. See Supplementary Fig. S1b. In order to 
characterize the CD8+ T cells, debris was gated out of bulk tumor based on forward 
scatter and side scatter. Dead cells were then gated out of the bulk tumor population and 
lymphocytes were subsequently selected as CD3+ and then gated by CD4 vs. CD8. To 
determine the activation state of CD8+ T cells, CD8+ cells were then gated by CD44 vs. 
CD62L as well as CD8 vs. granzyme-B. The exhaustion state of CD8+ T cells was 
determined by gating CD8+ cells by PD-1 vs. Lag3. In order to characterize the CD4+ T 
cells, debris was gated out of bulk tumor based on forward scatter and side scatter. Dead 
cells were then gated out of the bulk tumor population and lymphocytes were 
subsequently selected as CD3+ and then selected as CD4+. See Supplementary Fig. S2a. 
 
Ex vivo suppression assay 
Isolated G-MDSCs were co-cultured with peptide-specific stimulated T cells and 
quantified for T-cell proliferation. G-MDSCs were isolated from tumors following tumor 
dissociation as described above. Eluted G-MDSCs were co-cultured with 1x105 CSFE-
labeled CD8+ neu-specific T cells isolated from untreated neu-specific TCR-transgenic 
mice (38) at varying ratios (1:1 – 1:8 MDSC:T cells). Prior to plating, T-2Dq antigen 
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presenting cells (APCs) were pulsed with either R-neu420-429 or control peptide (NP) 0.4 
µg peptide for 4 hours; both purchased from the Johns Hopkins University Synthesis and 
Sequencing facility at greater than 95% purity. The APCs were simultaneously added to 
the co-cultured CD8+ T cells and MDSCs at a ratio of 2:1 APCs:T cells, and plates were 
incubated at 37°C for a total of 48 hours. Cells were then harvested, stained with 
Live/Dead NIR (ThermoFisher, cat. L10119) as well as CD8 and Thy1.2 and analyzed 
via flow cytometric analysis as described above. Dilutions of initial CFSE were 
indications of T cell divisions, where fewer divisions indicated greater suppressive G-
MDSC activity. All antibodies used are listed in Supplementary Table 1. 
Due to the small number of infiltrating M-MDSCs, we were unable to isolate sufficient 
numbers of these cells to perform a suppression assay. We attempted using flow 
cytometry as an alternative method of assessing M-MDSCs. However, the sorted M-
MDSCs had poor viability, which had confounding effects on this assay.  
 
Arginase assay 
Arginase activity was measured colorimetrically ex vivo using Abcam’s Arginase 
Activity Assay Kit (cat. ab180877). G-MDSCs were isolated from tumors and processed 
as described above and plated per manufacturer’s instructions. In short, cells were lysed 
with kit’s lysis buffer at 1x106/1mL, and plated in varying dilutions (30k or 60k cells per 
well) in duplicate in a flat-bottom, low-retention plate carefully to avoid bubble 
formation. Target samples were incubated for 20 minutes at 37°C with H2O2 substrate 
solution, while background wells were incubated with additional buffer. Standards were 
prepared per kit instructions, and the enzymatic reaction mixture was prepared and added 
to all wells. Raw absorbance values were immediately obtained over a 30-minute period 
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using a plate reader (Molecular Devices SpectraMax M3) at OD=570nm at 37°C. 
Arginase Activity Units were then calculated from raw absorbance values. ΔOD (ΔOD= 
(OD2-ODbg2)-(OD1-ODbg1)) was used to obtain the nmol of H2O2 generated by 
arginase, collected from a standard curve of known H2O2 concentrations. Arginase 
activity is calculated as (B/ΔT*V)*D in units/mL, where B is amount of H2O2 from 
standard curve (nmol), V is the sample volume added into reaction well (µL), D is sample 
dilution factor. One unit of Arginase activity refers to the amount of arginase that will 
generate 1.0 nmol of H2O2 per minute at pH 8 at 37°C. 
 
Gene expression profiling 
RNA was extracted from whole tumors or G-MDSCs isolated from tumors using the 
Qiagen RNeasy extraction kit (cat. 74104). Using a NanoDrop ND-1000, RNA quality 
and quantity were determined (samples with A260/280 < 1.8 were excluded). Gene 
expression was measured on the NanoString nCounter Analysis System (NanoString 
Technologies). The NanoString PanCancer Immune CodeSet (cat. XT-CSO-MIP1-12) 
was used to perform the nCounter Gene Expression Assay for whole tumor samples, 
whereas the Mouse Myeloid Innate Immunity CodeSet (cat. XT-CSO-MII2-12)  was used 
to perform nCounter Gene Expression Assay for isolated G-MDSCs. Quantification of 
target mRNA in each sample was performed by detection within the nCounter Digital 
Analyzer. The data obtained from the PanCancer Immune CodeSet were deposited on the 
public database GEO under the accession number GSE121031. The data obtained from 
the Mouse Myeloid Innate Immunity CodeSet were deposited on the public database 
GEO under the accession number GSE121030. 
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Gene expression analysis 
Data from the NanoString nCounter system was normalized to the internal positive 
controls and housekeeping genes using the recommended settings in the nSolver software 
normalization module (NanoString Technologies). Normalized data was exported and 
differential expression analysis was performed using a linear model method with the 
limma package (55) for the R programming language. To identify pathways which were 
differentially expressed in each treatment, the gage package (56) was used to test for 
differentially expressed KEGG pathways. Pathways of interest were visualized using the 
pathview package (57). 
 
QC plots for NanoString cell typing 
The QC plots show the correlation between genes included in the assay that are used to 
call specific cell types. nSolver uses expression data from Lag3, Cd244, Eomes, and 
Ptger4 to call the “Exhausted CD8” set and expression data from Cd6, Cd3d, Cd3e, 
Sh2d1a, Trat1, and Cd3g to call the “T-cell” set. These plots report how well the 
expression of the genes within each cell type set correlate with each other. In our data 
from the PanCancer Immune panel, the algorithm to call cell types uses Cd3g and Cd3d 
for “T cells” and Lag3 for “Exhausted CD8” cells. Due to the inherent variability 
between animals, more than the recommended 4 biological replicates are likely necessary 
to prevent the nSolver algorithm from discarding genes used to make cell type calls. See 






Reverse transcription of mRNA and subsequent qPCR was performed on RNA isolates to 
validate expression level changes seen in NanoString analysis. RNA extracted from 
isolated G-MDSCs and whole tumor (Qiagen RNeasy kit, cat. 74104) were normalized to 
10 ng/µL, and 1 μg of total RNA was used for reverse transcription. The SuperScript 
VILO cDNA Synthesis Kit (Invitrogen #11754050) was used following the 
manufacturer's instructions. qPCR of subsequent cDNA was performed using gene 
specific proprietary primer and probe constructs for selected genes obtained from 
TaqMan (ThermoFisher, see individual product numbers per gene), and used with 
TaqMan Universal Master Mix II, no UNG (Applied Biosystems #4440040) following 
manufacturer's instructions. qPCR was performed on the StepOnePlus real-time PCR 
system (Applied Biosystems). To validate the ERBb pathway, Tgfα (Mm00446231_m1) 
and Egf (Mm004438696_m1) were checked, for the mTOR pathway, Tgfα 
(Mm00446231_m1) and Frizzled4 (Mm00433382_m1) were checked, for the VEGF 
pathway, Vegfa (Mm01281449_m1) and Cox2 (Mm03294838_g1), were checked. For 
the Leukocyte transendothelial migration pathway, Pik3cg (Mm00445038_m1) and 
Vcam1 (Mm01320970_m1) were checked, for the osteoclast differentiation pathway, Infg 
(Mm01168134_m1), and Il1b (Mm00434228_m1) were checked. 18s (Mm04277571_s1) 
was used as a control and Stat3 (Mm01219775_m1) and Arg1 (Mm00475988_m1) were 
also checked. The 2-step real-time PCR cycling conditions used were 95 °C for 20 s, 40 
cycles of 95 °C for 3 s, and then 60 °C for 30 s. Gene expression was quantified from raw 
data by calculating mean CT values from the three replicates and comparing the ΔCT 
values of each gene to the 18s reference gene. Fold changes were quantified as 2^ΔΔCT 




G-MDSCs were isolated from whole tumor of treated animals using Miltenyi Biotec’s 
MDSC Isolation Kit and pooled by treatment group. Samples being used for phospho-
STAT3 analysis were subsequently stimulated with IL-6 at 20 ng/μl for 25 minutes. 
Samples were lysed in RIPA buffer with added 1μM DTT, 1μM PMSF, and 1:100 
protease/phosphatase inhibitor cocktail (Cell Signaling #5872S) and quantified by BCA 
(Pierce, #23225). 125μg of protein was run in 4-12% Bis-Tris gels under denaturing 
conditions. The LiCor Odyssey developing and imaging system was used, and the 
following primary antibodies were diluted in Odyssey Blocking Buffer (TBS) + 0.2% 
Tween® 20 at specified concentrations: Abcam Anti-Interferon gamma rabbit (1:1000), 
Abcam Anti-VEGFA rabbit (1:1000), Abcam Anti-EGF antibody (1:1000), Cell 
Signaling TNF-α Rabbit mAb (1:1000), Cell Signaling PI3 Kinase p110γ Rabbit mAb 
(1:1000), Cell Signaling Stat3 Rabbit mAb (1:2000), Cell Signaling Phospho-Stat3 
(Tyr705) Rabbit mAb (1:2000). Membranes were blocked with Odyssey blocking buffer 
TBS for 1hr and then incubated with primary antibody solution overnight at 4°C with 
gentle shaking. Membranes were washed with 1X TBS-T and subsequently incubated 
with the following secondary antibodies: 680RD Donkey anti-Chicken IgG (1:10,000), 
800CW Donkey anti-Rabbit IgG (1:10,000) in Odyssey Blocking Buffer (TBS) + 0.2% 
Tween® 20. Membranes were protected from light during incubation with secondary 
mixture for one hour at room temperature with gentle shaking. Membranes were 
subsequently washed with 1X TBS-T and imaged with the Odyssey® imaging system. 




For survival data, results were plotted using a Kaplan-Meier curve and statistical 
significance was determined via a log-rank test, (n = 10 mice/group). For tumor growth 
data, statistical significance was determined using a two-way analysis of variance 
(ANOVA) (n = 10 mice/group). For all flow and arginase data, mice were sacrificed 
during the third week of treatment. For dot plots, each dot represents one mouse and each 
bar represents mean ± SEM. (n = 3-5 mice/group). Significance was determined by a one-
way ANOVA with Tukey’s multiple comparisons test. All experiments were repeated at 
least 3 times. All statistical analysis listed here were performed using GraphPad Prism 




Supplementary Table 1 
  
Supplementary Table 1: Antibodies used for flow cytometry. All antibodies were 
titrated for use with specified flow cytometers.  
Target Color Clone Vendor, Catalogue # 
Arg-1 PE Polyclonal R&D Systems, IC586-8P 
CD11b AF700 M1/70 BD Biosciences, 557960 






BV510 BioLegend, 100234 
APC BD Biosciences, 565643 
CD4 
PE-Dazzle 
594 RM4-5 BioLegend, 100536 
AF700 ThermoFisher, 56-0042-82 
CD44 PE IM7 BD Bioscience, 553134 





Pacific Blue BioLegend, 100725 
BV510 BD Biosciences, 563068 
CTLA-4 PE UC10-4F10-11 BD Biosciences, 553720 
EOMES AF488 Dan11mag eBioscience, 53-4875-82 
F4/80 PE-Cy7 BM8 BioLegend, 123114 
BV510 BioLegend,  123135 
FoxP3 FITC FJK-16s ThermoFisher, 11-5773-82 
Granzyme B PE-Cy7 NGZB ThermoFisher, 25-8898-82 
INFg PerCP-Cy5.5 XMG1.2 ThermoFisher, 45-7311-82 
Lag3 PerCP-Cy5.5 C9B7W BD Biosciences, 564673 
Ly6C PerCP-Cy5.5 HK1.4 BioLegend, 128011 
eFluor450 ThermoFisher, 48-5932-82 
Ly6G FITC 1A8 BD Biosciences, 551460 




BD Biosciences, 565815 
APC BioLegend, 135210 
PE-Cy7 BioLegend, 135216 
PD-L1 PE-Dazzle 594 10F.9G2 BioLegend, 124324 
Tbet PE-Cy7 4B10 BioLegend, 644824 
Thy1.2 APC 53-2.1 BD Bioscience, 553007 
TIM3 eFluor450 8B.2C12 ThermoFisher, 48-5871-82 
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Supplementary Figure 1: Flow cytometry gating strategy to identify G- and M-
MDSCs. (a) Debris was excluded form bulk tumor based on forward scatter and side 
scatter. Single cells were then gated by forward scatter-area and forward scatter-height. 
Dead cells were then gated out of the single cell bulk tumor population. T cells and mature 
macrophages were gated out by selecting the CD3 and F4/80 double negative population. 
CD11b+ cells were then gated, and G- and M-MDSCs were identified using Ly6G vs. 
Ly6C. G-MDSCs were defined as Ly6G+ Ly6Clo and M-MDSCs were defined as Ly6G- 
Ly6C+. (b) Original flow cytometry T cell and MDSC panels gated out debris from bulk 
tumor based on forward scatter and side scatter. Dead cells were then gated out of the bulk 
tumor population. Bulk T cells were gated by selecting the CD45 and CD3 double positive 
population while bulk myeloid cells were gated by selecting the CD45 and CD11b double 
positive population. Subsequent gating of specific T cell and MDSC populations were then 
performed as described in Supplemental Fig. 1a and 2. 
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 Supplementary Figure 1 
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Supplementary Figure 2: Flow cytometry gating strategy to identify CD8+ T cell 
activation and exhaustion status and QC plots for NanoString cell typing. (a) Debris 
was excluded from bulk tumor based on forward scatter and side scatter. Dead cells were 
then gated out of the bulk tumor cell population and then gated by CD4 vs. CD8. To 
determine the activation state of CD8+ T cells, CD8+ cells were then gated by CD44 vs. 
CD62L as well as CD8 vs. granzyme-B. The exhaustion state of CD8+ T cells was 
determined by gating CD8+ cells by PD-1 vs. Lag3. The QC plot for the “T-cell” set (b) 
uses expression data from the genes Cd3g and Cd3d to call this cell type. The QC plot for 
the “exhausted CD8” (c) shows expression data from Lag3. 
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Baseline expression of immune checkpoints on bulk tumor and immune cells 
Previous studies have examined the expression of PD-L1 as a predictor of 
response and show varied correlation between protein expression and response (6,58,59). 
Thus, we evaluated changes in expression of PD-1, PD-L1, and CTLA-4 via flow 
cytometry in bulk tumors, as well as on intratumoral CD8+ T cells, CD4+ T cells, and 
MDSCs (cell types determined by gating strategies outlined in methods section) to 
determine if changes in expression following treatment with ENT alone validates a 
rationale for combining ICIs with ENT. We found no significant changes in expression of 
these checkpoint molecules on bulk tumor, as well as on intratumoral CD8+ T cells, CD4+ 
T cells, and MDSCs, with the exception of PD-1 expression on CD8+ T cells, which 
showed an increase in expression (Supplementary Fig. S3a-d). Thus, we considered that 
increased expression of checkpoint molecules within the TME may not be predictive of 
response to ICIs in our models. However, various groups have previously shown synergy 
between HDAC inhibition and various immunotherapies, including checkpoint inhibition, 
which does provide rationale for addition of these checkpoint inhibitors to ENT as 
completed in our study (29–31,51,52). Specifically, previous studies showed that in the 
4T1 breast cancer model, 5-azacytidine + ENT decreased infiltration of MDSCs into the 
tumor and concluded that it was ENT driving this effect (29). We also performed a 
comparison of the HDACis ENT and ACY-1215 as well as a demethylating agent (SGI-
110) in the murine PDAC model. We determined only ENT significantly improved 
survival over other drugs (Supplementary Fig. S4a). Thus, we chose to move forward 
using ENT given its efficacy in both tumor models. We substituted anti–PD-1 for GVAX  
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Supplementary Figure 3: Pre-treatment with ENT does not induce significant 
changes in expression of PD-1, PDL-1 or CTLA-4. Tumors were isolated from neu-N 
mice following no treatment (Untreated) vs. mice treated with ENT for 3 weeks (ENT). 
PD-1, PD-L1, and CTLA-4 expression were evaluated by FACS and cells were gated as 
follows: debris was gated out using forward and side scatter, live cells were selected 
following staining with Live/Dead Near IR, and respective positive populations for each 
checkpoint were quantified.  There were no significant changes in expression of PD-1, 
PDL-1 and CTLA-4 in bulk tumor (a), and on intratumoral CD8 (b), CD4 (c) and 
MDSCs (d) following treatment with ENT. For survival data, results were plotted using a 
Kaplan-Meier curve and statistical significance was determined via a log-rank test, (n = 
10 mice/group). For tumor growth data, statistical significance was determined using a 
two-way ANOVA (n = 10 mice/group). All experiments were repeated at least 3 times. 






























































Supplementary Figure 4: ENT improves survival over other HDACi’s and addition 
of ENT to checkpoint inhibition significantly improves survival and slows tumor 
progression. Initial experiments in the Panc02 model were done in combination with an 
allogeneic whole tumor cell vaccine that is engineered to secrete G-MCSF (GVAX) (50). 
Addition of ACY-1215 did not improve survival beyond that of GVAX alone and was 
inferior to ENT (a). Survival (b) and tumor growth (c) of neu-N mice receiving ENT and 
ICIs without anti-HER2. Statistics for tumor growth calculated at day 48. 
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as our immunotherapy, which yielded the same survival benefit when combined with 
ENT (Fig. 1b, Supplementary Fig. S4a). Thus, moving forward we used checkpoint 
inhibitors as our immunotherapy instead of GVAX. 
 
ENT priming sensitizes tumors to checkpoint inhibition and improves survival  
We hypothesized that ENT would sensitize naturally immune-resistant tumors, 
which often fail to recruit T cells into their TME, to ICIs. To test this hypothesis, we 
evaluated ENT given in combination with anti–PD-1, anti–CTLA-4, or a combination of 
the three drugs in neu-N/HER2+ breast cancer and Panc02 metastatic PDAC models. A 
final dosing schedule is shown in Fig. 1a. In the PDAC model, ENT+anti–PD-1, 
ENT+anti–CTLA-4, ENT+both ICIs, and anti-PD-1+anti-CTLA-4 significantly 
improved survival over treatment with vehicle or ENT alone (Fig. 1b). In the neu-N 
model, treatment with anti-HER2 significantly improves survival and inhibits tumor 
growth (Fig. 1c, 1d), consistent with studies showing efficacy in patients treated with 
HER-directed therapy (60). Combination ENT+anti–PD-1+anti-HER2, ENT+anti–
CTLA-4+anti-HER2, or ENT+anti-HER2+both ICIs significantly improved survival 
compared to vehicle or ENT alone in the neu-N breast tumor model (Fig. 1c). 
Combination immunotherapy alone did not improve survival when compared to vehicle 
or ENT (Fig. 1c). The combination of ENT+both ICIs in the absence of anti-HER2 
significantly improved survival (Supplementary Fig. S4b). Future studies will focus on 
the specific contribution of anti-HER2 to these therapies. However, for the remainder of 
the experiments presented herein, addition of anti-HER2 served to prove that the results 
were similarly efficacious (with and without it) to better inform the use of ENT+ICIs in  
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Figure 1: Addition of entinostat to checkpoint inhibition significantly improves 
survival and slows tumor progression. (a) Timeline of study design.  In the neu-N 
model, ENT treatment was started 3 days following tumor implantation. For the 
metastatic pancreatic cancer model, ENT treatment began 7 days after hemisplenectomy 
and tumor implantation. In both models, ENT was given for 5 consecutive days each 
week over the course of 3 weeks. ICI antibody dosing was performed biweekly, whereas 
anti-HER2 was given weekly. For survival studies, mice continued to receive two doses 
of ICI antibody as well as one dose of anti-HER2 (neu-N model only) every other week 
after the first three weeks of treatment. Mice did not continue to receive ENT after the 
first three weeks of treatment. This was considered the maintenance phase of treatment. 
For all immune infiltrate analyses, mice were sacrificed during the third week of 
treatment. (b) Survival of PDAC mice receiving ENT and ICIs. (c) Survival and (d) 
tumor growth of neu-N mice receiving ENT and ICIs with anti-HER2. Statistics for 
tumor growth were calculated at day 43. For survival data, results were plotted using a 
Kaplan-Meier curve and statistical significance was determined via a log-rank test, (n = 
10 mice/group). For tumor growth data, statistical significance was determined using a 
two-way ANOVA (n = 10 mice/group). All experiments were repeated at least 3 times. 









patients receiving ongoing anti-HER2 therapy. Combination therapies with ENT+single 
ICIs led to a significant decrease in tumor burden in the neu-N model, both with and 
without anti-HER2 (Fig. 1c, Supplementary Fig. S4c).  
 
Combined therapy shifts the TME from an M-MDSC to a G-MDSC dominated milieu  
 Given the improved antitumor immune responses observed in the mouse tumors, 
we next asked if ENT+ICIs were affecting MDSCs, as previous studies demonstrate 
decreased recruitment of MDSCs into the TME following similar therapies (29). To 
evaluate changes in MDSC populations, breast tumors and PDAC liver metastases were 
harvested following a full course of treatment. Immune cells were isolated and were 
characterized as G- and M-MDSCs via flow cytometry (Fig. 2a, Supplementary Methods 
Fig. S1a). Analysis showed that treatment with ENT in combination with anti–PD-1 or 
anti–CTLA-4 shifted the MDSC population to be dominated by the less 
immunosuppressive G-MDSCs (21) (Fig. 2b, 2c). Single-agent treatment with ENT 
significantly increased G-MDSCs in PDAC hepatic metastases (Fig. 2c), resembling the 
increase trends observed in the periphery of tumor-bearing neu-N mice (Supplementary 
Fig. S5a, S5b). However, the addition of ICIs was required to observe significant G-
MDSC induction in the primary breast tumors. The observed increase in G-MDSCs was 
not the result of a redistribution between the proportions of myeloid cells since treatment 
of mice with combination therapies significantly increased the absolute number of G-
MDSCs adjusted to tumor or liver weight (Supplementary Fig. S5c, S5d). Treatment with 
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Figure 2: ENT+ICIs significantly increases infiltration of G-MDSCs into the tumor 
microenvironment. (a) Gating strategy for identification of MDSCs by flow cytometry. 
G-MDSCs: CD3–F4/80–CD11b+Ly6G+Ly6Clo; M-MDSCs: CD3–F4/80–CD11b+Ly6G–
Ly6C+. (b) Changes in G-MDSC infiltration in breast tumors and (c) hepatic metastases 
of PDAC mice. (d) Changes in M-MDSC infiltration is in breast tumors of neu-N mice 
and (e) in hepatic metastases of PDAC mice. In all experiments, cells were isolated from 
breast tumors and livers containing PDAC metastases, respectively. For all flow data, 
mice were sacrificed during the third week of treatment. Each dot represents one mouse 
and each bar represents mean ± SEM. (n = 3-5 mice/group). Significance was determined 
by a one-way ANOVA with Tukey’s multiple comparisons test. All experiments were 
repeated at least 3 times. Statistically significant p values are abbreviated as follows: 


















Supplementary Figure 5: Both circulating MDSCs and absolute numbers of G-
MDSCs infiltrating neu-N and Panc02 tumors increase with entinostat treatment. 
Changes in peripheral G-MDSCs (a) and M-MDSCs (b) isolated from circulating blood 
of tumor bearing neu-N mice determined via flow cytometry. Cells were isolated from a 
minimum of 200 µl of circulating blood from neu-N mice. G-MDSCs quantified using 
flow cytometry from neu-N tumors (c) or from hepatic Panc02 metastases (d) normalized 
by weight of tumor or liver. For all flow data, mice were sacrificed during the third week 
of treatment. Each dot represents one mouse and each bar represents mean±SEM. (n = 3-
5 mice/group). Significance was determined by a one-way ANOVA with Tukey’s 
multiple comparisons test. All experiments were repeated at least 3 times. Statistically 
significant p values are abbreviated as follows: *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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ICIs alone did not alter MDSC infiltration into the TME compared to vehicle, and no 
significant difference in infiltration by M-MDSCs in either model was seen (Fig. 2d, 2e).  
 
ENT alters G-MDSC function, rendering them less immune suppressive 
 Because we observed increased recruitment of G-MDSCs into tumors of mice in 
the setting of decreased tumor burden, we evaluated the function of these cells. 
Traditionally, production of Arg-1 by MDSCs is used as a marker of their 
immunosuppressive capability (30). Thus, we performed immunosuppression assays and 
determined Arg-1 production both ex vivo and by flow cytometry. Data from 
immunosuppression assays revealed that the ability of G-MDSCs to suppress T-cell 
proliferation is inhibited in mice receiving ENT (Fig. 3a). Arg-1 protein expression was 
evaluated in both G- and M-MDSCs using a colorimetric arginase activity assay in the 
neu-N model (Fig. 3b, 3c) and by flow cytometry in the neu-N and PDAC models 
(Supplementary Fig. S6a-d). Results from both assays indicated that G- and M-MDSCs 
isolated from ENT+ICI-treated mice produced significantly less Arg-1. Taken together, 
these data suggest that the impaired immunosuppressive function of tumor-infiltrating G-
MDSCs is, at least in part, due to decreased Arg-1 production. Evaluation of PD-L1 was 
also investigated as a measure of MDSC suppressive cell function. We analyzed the 
surface expression of PD-L1 on intratumoral G-MDSCs by flow cytometry. PD-L1 
expression was significantly reduced on G-MDSCs with ENT+ICI treatment 
(Supplementary Fig. S6e, S6f). This suggested that treatment of G-MDSCs with ENT 
reduced their ability to inhibit T-cell activity by diminishing availability of the PD-
L1/PD-1 T-cell inhibitory pathway. 





























Figure 3: ENT+ICI combination therapy inhibits immunosuppressive functions of 
MDSCs. (a) Ly6G+ G-MDSCs isolated from breast tumors of individual animals were 
co-cultured with naïve neu-specific CD8+ T cells and peptide-pulsed APCs. Proliferation 
was determined by CFSE staining. Each bar is an average of 3-4 mice per treatment 
group. Error bars indicate mean±SEM. Significance was determined by a one-way 
ANOVA with Tukey’s multiple comparisons test. Changes in arginase activity of (b) G-
MDSCs and (c) M-MDSCs isolated from treated breast tumors determined via 
colorimetric assay. For arginase data, mice were sacrificed during the third week of 
treatment. Each dot represents one mouse and each bar represents mean±SEM. (n = 3-5 
mice/group). All experiments were repeated at least 3 times. Statistically significant p 
values are abbreviated as follows: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Supplementary Figure 6: Entinostat decreased expression of MDSC functional 
markers by flow cytometry and decreases expression of PD-L1—an alternative 
functional marker of G-MDSCs. Changes in expression of Arg-1 in G-MDSCs (a) and 
M-MDSCs (b) from neu-N tumors as evaluated by flow cytometry. Cells were isolated 
from breast tumors. Changes in expression of Arg-1 in G-MDSCs (c) and M-MDSCs (d) 
from livers containing PDAC metastases as evaluated by flow cytometry. Changes in 
expression of PD-L1 on G-MDSCs isolated from neu-N tumors (e) and from livers 
containing PDAC metastases (f) as evaluated by flow cytometry. For all flow data, mice 
were sacrificed during the third week of treatment. Each dot represents one mouse and 
each bar represents mean±SEM. (n = 3-5 mice/group). Significance was determined by a 
one-way ANOVA with Tukey’s multiple comparisons test. All experiments were 
repeated at least 3 times. Statistically significant p values are abbreviated as follows: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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ENT+ICI therapy significantly alters the signaling pathways involved in myeloid function 
ENT alters the global acetylation state of cells (61), but its effect on 
subpopulations of myeloid cells has not been thoroughly studied. To identify possible 
mechanisms for their impaired function, we utilized NanoString transcript profiling to 
evaluate broad changes in the transcriptome of isolated G-MDSCs induced by treatment. 
Treatment with ENT and subsequently anti–CTLA-4 and/or anti–PD-1 significantly 
altered the expression of many genes important to G-MDSC’s function (Fig. 4a). Further 
evaluation revealed relevant pathways that were significantly up- or downregulated and 
contained significantly altered genes that drove the differential regulation of these 
pathways (Fig. 4b, 4c, Supplementary Fig. S7a, S7b).  We narrowed our focus to certain 
pathways and genes that may be more specifically responsible for the observed MDSC 
phenotypes and only report treatment combinations that showed significant changes 
across all biological replicates (Fig. 4b, 4c). Our data reveal several observations. First, 
treatment with ENT alone and ENT+anti–PD-1 decreased expression of genes in both the 
ErbB and VEGF signaling pathways compared to vehicle-treated mice (Fig. 4b). 
However, expression was increased in both pathways in mice treated with ENT+anti–
CTLA-4 (Fig. 4c). Second, treatment with ENT+anti–PD-1 downregulated the mTOR 
pathway (Fig. 4b), whereas ENT+anti–CTLA-4 increased overall expression of the 
pathway (Fig. 4c). Fig. 4d depicts the VEGF pathway, highlighting key genes altered due 
to treatment with ENT compared to vehicle. Fourth, significant changes due to ENT+ICI 
treatment in pathways involving adhesion and motility suggested that treatment with 
ENT+ICI increased G-MDSC trafficking, which may explain the observed increased in 
infiltration of G-MDSCs (Supplementary Fig. S7a, S7b). Fifth, changes in pathways  
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Figure 4: HDACi+ICI combined therapy significantly alters the signaling pathway 
gene expression profiles involved in myeloid function. (a) Heatmap of gene expression 
changes in all-treatment groups compared to vehicle treatment alone. Red indicates 
upregulation and blue indicates downregulation. (b) Tables listing selected significantly 
downregulated KEGG pathways and (c) significantly upregulated KEGG pathways, with 
the top 5 genes differentially regulated listed in last column. (d) Differentially regulated 
genes in the VEGF signaling pathway in mice treated with ENT vs. vehicle. Expression 
of genes listed in white boxes were measured but did not show any fold change. 
Expression of genes in gray boxes were not measured. NanoString gene expression 
profiling was performed once with at least 4 mice per group. Statistically significant p 
values are abbreviated as follows: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Supplementary Figure 7: HDACi + ICI combined therapy significantly alters 
patterns of myeloid cell functional markers on gene expression profiling. Table listing 
all significantly downregulated (a) and significantly upregulated (b) KEGG pathways, with 
the top 5 genes differentially regulated listed in last column. Selected genes alternately 
regulated by given treatment with p-values and fold change (c). The complete list of 
individual genes significantly up or downregulated was over 100 genes in length and too 
cumbersome for publication. Please contact corresponding author for inquiries. NanoString 
gene expression profiling was performed once with at least 4 mice per group. Statistically 
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controlling different hormone production, apoptosis, and MAPK signaling were observed 
(Supplementary Fig. S7a, S7b). Finally, we found over 100 significantly differentially 
expressed genes independent of the aforementioned pathways. Key genes of interest are 
listed (Supplementary Fig. S7c). Expression of significantly altered pathways and genes 
of interest were validated using quantitative-PCR (qPCR) (Supplementary Fig. S8). We 
also validated these findings by investigating changes in protein expression via western 
blot. EGF expression was analyzed to represent the ErbB pathway, VEGFA for the 
VEGF pathway, and TNFa for the mTOR pathway. Protein expression of STAT3, a key 
gene of interest, was evaluated along with activation of the STAT3 protein via 
phosphorylation at Tyr705. These data show that although the protein expression changes 
observed in G-MDSCs isolated from treated mice did not correlate with changes seen at 
the mRNA level (Supplementary Fig. S9a, S9b, Supplementary Fig. S7c), a decrease in 
phospho-STAT3 was observed in treated mice (Supplementary Fig. S9a, S9b), indicating 
a decrease in STAT3 activity. Changes in protein expression of EGF, VEGFA, and 
TNFa correlated with mRNA expression in groups treated with ENT+anti–CTLA-4 
compared to ENT-treated animals (Supplementary Fig. S9c). Changes in protein 
expression of EGF correlated with mRNA expression in groups treated with ENT 
compared to vehicle-treated animals (Supplementary Fig. S9d). However, changes in 
EGF protein expression did not correlate with mRNA expression in the ENT+anti–PD-1 
group compared to vehicle-treated animals (Supplementary Fig. S7c, S9e). No correlation 
between changes in VEGFA protein expression and mRNA expression in either the ENT 
or ENT+anti–PD-1 groups was seen (Supplementary Fig. S9d, S9e), as well as for TNFa 







































Supplementary Figure 8: qPCR validation of the NanoString platform. 
Reverse transcription of mRNA and subsequent qPCR was performed on RNA isolates to 
validate expression level changes seen in NanoString analysis. RNA was extracted from 
isolated G-MDSCs and whole tumor. Gene expression was quantified from raw data by 
calculating mean CT values from the three replicates and comparing the ΔCT values of 
each gene to the 18s reference gene. Fold changes were quantified as 2^ΔΔCT and plotted 
against corresponding NanoString fold change values. 
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Supplementary Figure 9: Changes in protein expression of STAT3, phospho-STAT3 
and representative proteins from pathways identified by NanoString. Protein levels of 
EGF (representative of the ErbB pathway), VEGFA (representative of the VEGF pathway), 
TNFa (representative of the mTOR pathway), STAT3, and phospho-STAT3 in G-MDSCs 
isolated from the TME of treated animals were determined via western blot analysis. (a) 
Representative western blots depicting changes in STAT3 and phospho-STAT3 expression 
in treated animals in the neu-N model (b) Quantification of fold changes in STAT3 and 
phospho-STAT3 expression in treated mice in the neu-N mode normalized to vehicle or 
ENT as indicated. (c) Fold change in expression of EGF, VEGFA, and TNFa in ENT+anti-
CTLA-4 treated animalsnbnormalized to ENT (d) Fold change in expression of EGF and 
VEGFA in ENT treated animals normalized to vehicle (e) Fold change in expression of 
EGF, VEGFA, and TNFa in ENT+anti-PD-1 treated animals normalized to vehicle. Each 
blot represents G-MDSCs isolated from whole tumor of treated neu-N mice. Five animals 






































focus on changes in expression of both genes and proteins within these pathways to 
determine if they play a mechanistic role in altered G-MDSC function. 
 
ENT+ICIs promote infiltration of effector CD8+ T cells independent of Treg infiltration 
After determining that ENT+ICIs inhibited the immunosuppressive function of G-
MDSCs, we sought to establish whether this change was sufficient to promote infiltration 
of functioning CD8+ T cells into the TME (51). Cells were isolated from tumors and 
changes within the T-cell populations were evaluated using flow cytometry. We observed 
increased infiltration of CD8+ T effector cells and decreased naïve and memory CD8+ T 
cells when ENT was combined with anti–PD-1, anti–CTLA-4, or both (Fig. 5a, 5b). 
Evaluation of the proliferative capacity of infiltrating CD8+ T cells within the PDAC 
TME showed increased proliferation with the addition of ICIs, determined by Ki67 
staining (Supplementary Fig. S10a). PDAC mice treated with ENT+anti–CTLA-4 also 
showed a significant increase in granzyme-B–producing CD8+ T cells. A pattern 
suggesting an increase in granzyme-B–producing CD8+ T cells was also observed in the 
anti-HER2+ENT+anti–CTLA-4-treated neu-N mice. The addition of anti–PD-1 reduced 
this effect in both tumor types (Fig. 5c, 5d). IFNg production by CD8+ T cells was also 
measured. However, combination-treated mice only showed a trending increase in both 
models (Supplementary Fig. S10b, S10c). These data indicate that the combination of 
ENT with ICIs induced infiltration of effector CD8+ T cells with cytotoxic capabilities.  
Although the CD8+ T cells appeared to exhibit improved antitumor activity, we wanted to 
characterize the ability of treatment to promote T-cell activation versus exhaustion. We 
evaluated the expression of various surface markers in CD8+ T cells from tumors in both  
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Figure 5: HDACi+ICI combination therapy promotes infiltration of activated 
cytotoxic CD8+ effector T cells. The proportion of infiltrating CD8+ naïve 
(CD62L+CD44–), effector (CD62L–CD44+), and memory (CD62L+CD44+) T cells was 
evaluated. (a) The percentage of infiltrating CD8+ effector T cells in breast tumors and 
(b) PDAC hepatic metastases of treated mice. (c-f) Cells were isolated from breast 
tumors and livers containing PDAC metastases, respectively. (c) Change in infiltration of 
CD8+ granzyme-B+ T cells in breast tumors and (d) PDAC hepatic metastases of mice 
receiving combined therapy. (e) Exhaustion state of infiltrating CD8+ T cells determined 
by co-expression of PD-1 and Lag3 in both the neu-N and (f) the PDAC model. For all 
flow data, mice were sacrificed during the third week of treatment. Each dot represents 
one mouse and each bar represents mean ± SEM. (n = 3-5 mice/group). Significance was 
determined by a one-way ANOVA with Tukey’s multiple comparisons test. All 
experiments were repeated at least 3 times. Statistically significant p values are 
abbreviated as follows: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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Supplementary Figure 10: Combination therapy induces T cell proliferation within 
the TME but does not significantly increase IFNg production. Changes in the 
proliferative capacity of CD8+ T cells within the TME of PDAC metastases, as determined 
by Ki67 staining (a). Changes in IFNg production in CD8+ T cells in either neu-N (b) or 
PDAC (c) models. For all flow data, mice were sacrificed during the third week of 
treatment. Each dot represents one mouse and each bar represents mean±SEM. (n = 3-5 
mice/group). Significance was determined by a one-way ANOVA with Tukey’s multiple 
comparisons test. All experiments were repeated at least 3 times. Statistically significant p 




models, and first observed significantly increased expression of PD-1 (Supplementary 
Fig. S11a, S11b). Because PD-1 can be a sign of activation as well as exhaustion, we 
evaluated the co-expression of a second marker Lag3. Co-expression of these molecules 
is indicative of exhausted CD8+ T cells, whereas the absence of Lag3 on PD-1+ CD8+ T 
cells is indicative of activated T cells (62,63). Our results only showed a significant 
increase in PD-1+Lag3–CD8+ T cells infiltrating tumors from both models (Fig. 5e, 5f). 
We noted a pattern of non-significant increases of exhausted PD-1+Lag3+CD8+ T cells 
(Supplementary Fig. S11c, S11d). These data support that most CD8+ T cells infiltrating 
tumors in response to ENT+ICIs were activated and not exhausted. We also checked the 
co-expression of Tim3 and CTLA-4 with PD-1 as additional markers of exhaustion 
(62,63) and found similar trends. Analysis of transcription factor expression revealed a 
50% increase in terminally exhausted CD8+ T cells in mice treated with ENT+anti-PD-
1+anti+CTLA-4 in both neu-N tumors and PDAC metastases (Supplementary Fig. S11e, 
S11f). These are also the treatment groups with the highest proliferative capacity. This 
analysis showed no significant change in progenitor exhausted CD8+ T cells in the neu-N 
model and a 35-60% increase in the PDAC model (Supplementary Fig. 11g, 11h). Taken 
together, these data support that treatment generally induces an activated T-cell state. 
Previous studies revealed that ENT+interleukin-2 induces a decrease in tumor burden, 
which correlates with an increase in effector T cells and a reduction in tumor-infiltrating 
regulatory T cells (Tregs) (33). Because Tregs have also been described as a major 
immunosuppressive component of the TME (64), we used flow cytometry to determine if 
ENT altered Treg infiltration. However, we only observed a trending decrease in Tregs in 
both models (Fig. 6a, 6b), which was not statistically significant. 
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Supplementary Figure 11: The effect of ENT+ICIs on the exhaustion state of CD8+ T 
cells. Change in infiltration of CD8+ T cells expressing PD-1 in both neu-N (a) and PDAC 
(b) models. Co-expression of PD-1 and Lag3 on infiltrating CD8+ T cells in the neu-N (c) 
or the PDAC (d) models. Changes in infiltration of terminally exhausted CD8+ T cells (PD-
1hi EOMEShi) in tumors of neu-N mice (e) and in the PDAC model (f). Changes in 
infiltration of progenitor exhausted CD8+ T cells (PD-1hi Tbetint) is observed in neu-N 
tumors (g) and in PDAC metastases (h). For all flow data, mice were sacrificed during the 
third week of treatment. Each dot represents one mouse and each bar represents 
mean±SEM. (n = 3-5 mice/group). Significance was determined by a one-way ANOVA 
with Tukey’s multiple comparisons test. All experiments were repeated at least 3 times. 
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Figure 6: HDACi+ICI combination therapy does not  cause reduction in Treg 
infiltration. Changes in Treg infiltration in breast tumors of (a) neu-N mice and (b) 
hepatic metastases of PDAC mice receiving therapy. Cells were isolated from breast 
tumors and livers containing PDAC metastases, respectively. For all flow data, mice were 
sacrificed during the third week of treatment. Each dot represents one mouse and each 
bar represents mean ± SEM. (n = 3-5 mice/group). Significance was determined by a one-
way ANOVA with Tukey’s multiple comparisons test. All experiments were repeated at 
least 3 times. Statistically significant p values are abbreviated as follows: *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.  
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ENT + ICIs significantly alters gene expression profiles in immune signaling pathways  
Our data showed that ENT broadly impacted multiple populations of immune cells 
within the TME. Thus, we performed general immune transcriptome profiling on whole 
tumors isolated from the neu-N model using a PanCancer immune-profiling gene panel 
for the NanoString platform. Numerous significant changes were found in multiple genes 
and pathways (Fig. 7a). Specifically, two pathways were found to be significantly altered 
(listed in the table in Fig. 7b). We only report treatment combinations that showed 
significant changes. One of these pathways, leukocyte trans-endothelial migration, was 
upregulated, suggesting a mechanism by which leukocytes may be able to traffic into the 
TME and contribute to an antitumor response in mice treated with ENT+anti–CTLA-4 
(Fig. 7b). The osteoclast differentiation pathway was significantly upregulated in tumors 
from mice treated with ENT+anti–CTLA-4 vs. ENT alone (Fig. 7b). Many of the genes 
involved in this pathway were also involved in pathways that contribute to the regulation 
of adaptive immunity. Our experiments also identified 20 individual genes significantly 
altered in cells from whole tumors treated with ENT+anti–CTLA-4 and ENT+anti–
CTLA-4+anti–PD-1 (Supplementary Table 2). Detailed investigation of these genes is 
necessary to determine how other immune compartments are being affected. Use of 
NanoString enables evaluation of immune cell subsets and related pathways. However, 
none of the immune cell subsets were significantly altered in this evaluation. Fig. 7c 
demonstrates an increase in gene expression profiles that suggest both “T cells” 
(determined by expression of Cd3g and Cd3d) and “exhausted CD8” (determined by 
expression of Lag3) showed a trending increase in treated groups, corroborating findings 
from flow cytometry (Fig. 5). QC plots depicting the correlations of the genes used to call 
these cell types are included in Supplementary Fig. S2b, S2c. Platforms for more directed 
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approaches to investigation of gene expression profiling are still evolving and can be 
limited in feasibility by large cohort animal studies, as seen with our findings using the 
NanoString platform. Future studies will evaluate gene expression at the single-cell level 




Figure 7: HDACi+ICI combination therapy significantly alters the leukocyte 
transendothelial migration pathway. (a) Heatmap of gene expression changes 
comparing all treatment groups using the PanCancer Immune profiling gene set. Red 
indicates upregulation and blue indicates downregulation. (b) Table of significantly 
altered KEGG pathways. 5 most differentially expressed genes listed in last column. (c) 
Graphs depicting an increase in genes indicative of bulk T cells and exhausted T cells in 
combination treated groups. Genes upregulated listed in red, and genes downregulated 
are in blue. Expression of genes listed in white boxes were measured but did not show 
any fold change. Expression of genes in gray boxes were not measured by the assay. (d) 
Diagram showing proposed mechanism regulating decreased suppressive function of 
myeloid cells and increased infiltration of T cells as a result of treatment with ENT, anti–
PD-1, and anti–CTLA-4. NanoString gene expression profiling was performed once with 
at least 4 mice per group. Statistically significant p values are abbreviated as follows: 







    









































Supplementary Table 2: HDACi + ICI combined therapy significantly alter gene 
expression of genes involved in innate and adaptive immunity. Table of all genes 
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 We demonstrated in the neu-N and PDAC models that mice treated with the 
combination of ENT+ICIs exhibited significantly improved survival compared to mice 
treated with either ENT or ICIs alone. We also showed that the efficacy of ENT+anti–
CTLA-4 treatment was associated with a significant increase in tumor-infiltrating G-
MDSCs that exhibited impaired immunosuppressive function. We also identified changes 
in important signaling pathways that converged to control and regulate myeloid 
immunosuppressive activities, which suggest novel mechanisms responsible for the 
observed MDSC dysfunction in tumors. ENT was primarily responsible for significantly 
affecting genes controlling myeloid function, such as those within the VEGF and ErbB 
pathways, and may have also acted to prime CD8+ T cells by increasing their expression 
of PD-1. The addition of anti–PD-1 further augmented these changes, resulting in altered 
signaling in the mTOR pathway. The combination of ENT+anti–CTLA-4 induced 
changes in expression of downstream signaling molecules, at which the three pathways 
converged, leading to a similar outcome on myeloid suppression. These data showed that 
it was the addition of ICIs to ENT that led to improved infiltration of activated CD8+ T 
effector cells and increased cytotoxic characteristics. Examination of gene expression 
changes in whole tumors revealed that addition of anti–PD-1 and/or anti–CTLA-4 
affected T-cell trafficking. Taken together, these data elucidate a suggested mechanism 
by which ENT alters the function of myeloid cells and the addition of ICIs to ENT further 
alters the myeloid compartment and improves T-cell responses. This mechanistic 
understanding delineates the important effects of each individual drug on specific 
immune compartments within the TME. These data could be used for developing 
scientifically driven combinations of epigenetic- and immune-based therapies.  
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Various studies have shown that ENT can reduce tumor burden and alter MDSC 
infiltration, facilitating increased efficacy of single agent ICIs in other murine models of 
cancer (29–31,51,52). These data support the therapeutic strategy of using agents that 
target multiple immune compartments within the TME, where ENT inhibits the 
immunosuppressive myeloid populations and ICIs allow for the activation and 
recruitment of T cells in order to induce a robust antitumor response. We showed that 
whereas ENT+anti–PD-1+anti–CTLA-4 was efficacious, it did not significantly improve 
survival over ENT+anti–PD-1 or ENT+anti–CTLA-4. A previously proposed mechanism 
for improved survival is that addition of ENT to anti–PD-1 leads to decreased 
immunosuppressive capacity of tumor-infiltrating MDSCs and allows for increased 
infiltration of cytotoxic T cells (30). We not only confirmed these findings in breast and 
PDAC models but also expanded upon them by showing a decrease in Arg-1 protein 
activity and production (30). Given that our data were generated entirely ex vivo, it 
supports changes in Arg-1 protein production as a significant mechanism underlying the 
MDSC impairment reported. In further support of this proposed mechanism, our gene 
expression profiling of isolated G-MDSCs allowed us to identify changes specific to the 
G-MDSC transcriptome in key signaling pathways such as VEGF, mTOR, and ErbB. 
Changes in Arg-1 and PD-L1 protein expression have not been analyzed in human 
MDSCs treated with ENT. However, a clinical trial has analyzed changes in MDSC 
populations as well as changes in CD40. CD40 has previously been described to be 
necessary in human MDSC-mediated T-cell suppression (65). Tomita et al. show that 
treatment of breast cancer patients with ENT significantly decreases CD40 expression 
(32), suggesting ENT may also induce immunosuppressive dysfunction in human 
MDSCs.  
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The most impactful finding of our work is the identification of changes in gene 
expression responsible for the impaired immunosuppressive functions of G-MDSCs that 
are driven by ENT. First, we observed downregulation of genes within the VEGF 
signaling pathway in isolated G-MDSCs in ENT or ENT+anti–PD-1–treated versus 
vehicle-treated mice. Previous studies showed that elimination of VEGF can abrogate 
Arg-1 protein expression in intratumoral MDSCs and subsequently their ability to 
suppress T-cell proliferation (66), highlighting the importance of VEGF signaling in 
immunosuppressive functions of MDSCs. Second, decreased expression of genes in the 
ErbB signaling pathway were seen in isolated G-MDSCs with ENT or ENT+anti–PD-1 
treatment. This may also contribute to the decrease in suppressive nature of these cells 
because EGFR-deficient macrophages are known to produce less immunosuppressive 
factors, including Arg-1 (67). Taken together, ENT appears to be the treatment driving 
these observed changes, indicating that it may be inducing MDSC dysfunction by 
decreasing signaling within both pathways (Fig. 7d). Third, treatment with ENT+anti–
PD-1 significantly decreased expression of genes within the mTOR pathway. It has 
previously been shown that inhibition of mTORC1 can disrupt the immunosuppressive 
abilities of myeloid cells, including Arg-1 protein expression (68,69).  Therefore, it is 
possible that PD-1 inhibition also contributes to the observed MDSC dysfunction through 
decreased mTOR signaling (Fig. 7d). We evaluated protein expression of representative 
proteins for each pathway in order to attempt to validate the observed changes in gene 
expression of each pathway. Although some of these observed gene expression changes 
correlated with similar changes in protein expression, others did not. This was expected 
given that post-transcriptional modifications often cause discrepancies between levels of 
mRNA and protein. The reported changes in overall pathways were not determined by 
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changes in expression of single genes, rather the cumulative change of all genes in the 
pathway. Thus, expression of individual genes within a pathway were not representative 
of the overall reported pathway changes. Key genes directly affecting MDSC function 
will need to be identified before further protein analysis is pursued.  
Gene expression within the mTOR, ErbB, and VEGF pathways were upregulated 
with ENT+anti–CTLA-4 treatment, although this treatment also inhibited MDSC 
function similar to the combination of ENT+anti–PD-1. We hypothesize that these 
differential gene expression changes across treatment groups may converge at the 
transcription factor Stat3, which is downstream of all of the pathways we have mentioned 
(67,70). STAT3 is known to be essential in MDSC immunosuppressive function (27) and 
has previously been shown to be specifically targeted by ENT in MDSCs in in vitro 
systems (24,30,71,72). G-MDSCs from mice treated with ENT+anti–CTLA-4 showed a 
significant decrease in Stat3 expression, whereas significant downregulation in upstream 
activators were observed in the ENT or ENT+anti–PD-1 treated groups. This suggests 
that the ultimate change in regulation of Stat3 occurs either directly or indirectly 
depending on ICI treatment but leads to the same effect on G-MDSC function. The 
ENT+anti–CTLA-4 treated mice also exhibited a significant decrease in the expression of 
Vegfa, which has been shown to be a target of STAT3 transcriptional activity (73–75). 
Despite the increase in signaling intermediates in this pathway, a decrease in Vegfa 
expression, and subsequent VEGFR2 signaling, could be caused by less STAT3 activity. 
This could help explain the observed MDSC dysfunction with ENT+anti–CTLA-4, as 
inhibition of VEGFA signaling can prevent Arg-1 production (Fig. 7d) (66).  G-MDSCs 
from ENT+anti–CTLA-4 treated mice did show lower expression of Arg1 compared to 
the mice receiving ENT+anti–PD-1, further indicating that inhibition of STAT3 signaling 
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may be one of the driving mechanisms in the observed MDSC dysfunction. Taken 
together, we hypothesize that the mTOR, ErbB, and VEGF signaling pathways converge 
at Stat3 to drive immunosuppressive functions of MDSCs. This hypothesis requires 
significantly more investigation but given previous studies linking treatment with ENT to 
STAT3 activity (30) and linking STAT3 to the suppressive function of Arg-1 (27), this 
seems like a plausible explanation for our observations. Analysis of protein expression of 
STAT3 from neu-N mouse model did not follow the same trends as those observed at the 
mRNA level. However, investigation of phospho-STAT3 in isolated G-MDSCs showed a 
decrease in STAT3 phosphorylation in all treatment groups compared to vehicle, 
indicating decreased STAT3 activity may play a role in the observed MDSC dysfunction 
in treated animals. It has been shown that HDAC2 is important in the regulation of 
inflammatory genes in myeloid cells (54), suggesting class I HDACs may play a role in 
the regulation of Arg-1 (53). Lastly, it should be noted that preliminary work using the 
HDAC6 inhibitor ACY-1215 did not improve survival when combined with 
immunotherapy, suggesting class II HDACs may not play a pivotal role in the functional 
capabilities of MDSCs. This is an area where future studies can aim to delineate the roles 
of class I and II HDACs in MDSC function as well as Stat3 regulation. 
Whereas modulation of MDSC function seemed primarily responsible for the 
improved survival observed with ENT+ICIs in these models, the addition of ICIs also 
significantly improved the infiltration and cytotoxic ability of CD8+ T effector cells 
within the TME. We identified significant upregulation of the leukocyte trans-endothelial 
migration pathway, which likely aids in the infiltration of TILs, and the addition of anti–
CTLA-4 to ENT droves this observed change. The 20 genes that were found to be 
significantly affected by treatment with ENT+anti–CTLA-4 seemed to be expressed in a 
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wide range of immune cell types. This suggests cell types, such as dendritic cells and 
natural killer cells, may also be secondarily affected by ICIs but are not primarily 
responsible for improved survival in response to treatments in these tumor models. The 
observed increase in infiltration of activated T cells may also be explained by the 
induction of expression of immunogenic non-coding long terminal repeats (LTRs) in 
tumor cells. A study by Brocks et al. shows that treatment with both a DMNTi and an 
HDACi leads to activation of these LTR elements (76). In the future, we will examine 
whether treatment with ENT without DNMTi can induce a biologically relevant amount 
of LTR expression in vivo. 
In summary, these data support the use of ENT as a method of sensitizing non-
immunogenic tumors to ICI therapy.  ENT primed the MDSC compartment of the TME 
to permit T-cell infiltration into tumors thereby making them available for activation by 
ICI therapy. ICI therapy may also contribute to reprogramming MDSCs in favor of T-cell 
activity. These data have provided a deeper understanding of how to improve response to 
ICIs in patients with breast and pancreatic cancers. Specifically, they are informing the 
laboratory correlates for our clinical trials evaluating ENT+combined ICIs in advanced 
solid tumors with a dose expansion in advanced breast cancer (NCT02453620), as well as 
ENT+nivolumab in patients with unresectable PDAC (NCT03250273). The preclinical 
work presented here will provide the necessary scientific evidence to create rational 
combinations of immune therapies in future clinical trials in order to maximize efficacy 




CHAPTER 2: Validating the J774M cell line to determine the role of STAT3 in 
entinostat-induced MDSC reprogramming 
  
Summary 
 In order to further investigate the role of STAT3 in MDSC immunosuppressive 
dysfunction, we validated the previously described MDSC-like qualities of the J774M 
cell line. Identification and validation of an in vitro model for MDSC suppression is 
essential for downstream molecular analysis of MDSC function, as isolated intratumoral 
MDSCs are often fragile and difficult to culture. We found ENT inhibits 
immunosuppressive function and STAT3 phosphorylation in a manner that is similar to 
our previous observations in our in vivo studies. Specifically, we showed that the J774M 
cell line expresses surface markers similar to intratumoral MDSCs. Additionally, we 
demonstrated J774M cells were capable of producing functional Arg-1 and could 
suppress T cell proliferation in a dose-dependent manner. Similar to intratumoral 
MDSCs, both of these immunosuppressive functions could be inhibited with ENT 
treatment. We also found that ENT treatment inhibits STAT3 phosphorylation in J774M 
cells, which we have observed in isolated intratumoral G-MDSCs treated with ENT and 
ICI combinations in models of pancreatic and breast cancer. Taken together, these data 
suggest that the J774M cell line is an appropriate model to use for further evaluation of 
the role of STAT3 in MDSC biology as well as in the context of ENT-induced MDSC 
immunosuppressive dysfunction.  
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Introduction 
We and others have shown that inhibition of class I HDACs can impair the 
immunosuppressive functions of MDSCs in the TME and improve efficacy of ICIs in 
murine models. These studies have shown that use of the HDACi ENT can result in the 
inhibition of MDSC suppression of T cell proliferation ex vivo (30,77). These data show 
that ENT treatment of MDSCs decreases the expression of key immunosuppressive 
factors, such as Arg-1, PD-L1, iNOS, and COX2 (78). While the exact mechanism 
driving these functional changes still remain elusive, our work has identified STAT3 as a 
potential target of ENT, where ENT treatment causes a decrease in signaling pathways 
regulated by STAT3 and a decrease in phospho-STAT3 expression (77). Additionally, 
Orillion et. al has shown that ENT treatment of MDSCs increases acetylation of lysine on 
immunoprecipitated STAT3 (30), which has previously shown to inhibit STAT3 
phosphorylation and activity (31). Indeed, it has previously been shown that STAT3 is an 
important driver of MDSC proliferation and function (24,79). Various works have shown 
that STAT3 activity is essential for the induction of MDSCs (25,26) and inhibiting 
STAT3 ablates the immunosuppressive function of MDSCs (27,28) . Specifically, it has 
been shown that STAT3 phosphorylation is directly associated with Arg-1 activity in 
MDSCs and inhibition of STAT3 can prevent MDSC suppression of T cell proliferation 
(27).  
Given the effects of ENT treatment on post-translational modifications of STAT3 
as well as the similar functional impact of ENT treatment and STAT3 inhibition on 
MDSCs, we reasoned that ENT may be altering the ability of STAT3 to bind the 
promoters of key immunosuppressive genes. In order to investigate this, we developed an 
ex vivo intratumoral MDSC system and validated the MDSC-like cell line J774M to 
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perform chromatin-immunoprecipitation-sequencing (ChIP-Seq) and evaluate changes in 
localization of phospho-STAT3 to the promoters of immunosuppressive genes in ENT-
treated MDSCs. We confirm a decrease in phospho-STAT3 with ENT treatment in both 
the neuN and Panc02 murine models of breast and pancreatic cancer, respectively. 
Additionally, we show that ENT can inhibit the ability of J774M cells to produce Arg-1 
and suppress T cell proliferation, which is correlated with a decrease in phospho-STAT3 
levels. Taken together, these data validate the J774M cell line as a model of MDSC 
suppression and further supports the role of STAT3 in ENT-mediated MDSC 
reprogramming. This is an essential step in determining the molecular mechanisms 
behind altered MDSC function, as the fragility and short ex vivo life span of intratumoral 
MDSCs make robust molecular studies very difficult. 
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Materials and Methods 
Mice and cell lines 
All animal studies were approved by Institutional Review Board of Johns Hopkins 
University. Animals were kept in pathogen-free conditions and were treated in 
accordance with institutional and American Association of Laboratory Animal 
Committee policies. The neu-N mice were originally from W. Muller McMaster 
University, Hamilton, Ontario, Canada. Colonies were renewed yearly from Jackson labs 
and bred in house by brother/sister mating. For studies of metastatic pancreatic cancer, 
we used male C57BL/6J (The Jackson Laboratories, stock #000664) mice. For co-culture 
experiments with J774M cells, female Balb/c mice (The Jackson Laboratories, stock 
#000651) were used. 
All cell lines were regularly tested for Mycoplasma every three months in accordance to 
laboratory policy. NT2.5 cells were derived from spontaneous mammary tumors growing 
in female neu-N mice. In vitro cell lines were established and authenticated as previously 
described (39,40). Culture conditions for NT2.5 cells were as follows: 37°C, 5% CO2 in 
RPMI 1640 (Gibco, cat. 11875-093) supplemented with 20% fetal bovine serum (Gemini, 
cat. 100-106), 1.2% HEPES buffer (Gibco, cat. 15630-080), 1% L-glutamine (Gibco, cat. 
25030-081), 1% MEM non-essential amino acids (Gibco, cat. 11140-050), 0.5% 
penicillin streptomycin (Gibco, cat. 15140-122), 1% sodium pyruvate (Sigma, cat. 
S8636), 0.2% insulin (NovoLog, cat. U-100), 0.02% gentamicin (Sigma, cat. G1397). 
Panc02 is a murine pancreatic tumor cell line with ductal morphology derived from a 
methylcholanthrene-treated C57B1/6 mouse and authenticated as previously described 
(41,42). Culture conditions for Panc02 cells were as follows: 37°C, 10% CO2 in DMEM 
(Gibco, cat. 11965-084) supplemented with 10% fetal bovine serum (Gemini, cat. 100-
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106), 1% L-glutamine (Gibco, cat. 25030-081), 0.5% penicillin streptomycin (Gibco, cat. 
15140-122).  
J774M is an MDSC-like cell line was developed by FACS sorting CD11b+ Gr1+ cells 
from the ATCC macrophage line J774A.1 and have previously been shown to exhibit 
immunosuppressive functions similar to MDSCs (30,80,81).  Culture conditions for 
J774M cells were as follows: 37°C, 5% CO2 in RPMI 1640 (Gibco, cat. 11875-093) 
supplemented with 10% fetal bovine serum (Gemini, cat. 100-106), 1.5% HEPES buffer 
(Gibco, cat. 15630-080), 1% L-glutamine (Gibco, cat. 25030-081), 1% MEM non-
essential amino acids (Gibco, cat. 11140-050), 1% penicillin streptomycin (Gibco, cat. 
15140-122), 1% sodium pyruvate (Sigma, cat. S8636), 0.0004% beta-mercaptoethanol 
(Sigma, cat. M3148).  
 
Neu-N ex vivo studies 
The neu-N model is a syngeneic model whereby NT2.5 cells that were derived from a 
spontaneous mammary tumor are implanted via injection of 5 x 104 cells into the 
mammary fat pad of 7-8 week old female neu-N mice (39). 
 
Tumor dissociation 
To obtain single-cell suspensions from breast tumors, tumors were harvested, weighed, 
diced, and then dissociated using a tumor dissociation kit (Miltenyi Biotec, cat. 130-096-
730) and the OctoDissociator (Miltenyi Biotec) per the manufacturer’s instructions. The 
37C_m_TDK_2 program was used to dissociate tumors per the manufacturer’s 
instructions. Samples were filtered using a 40 µm cell strainer and red blood cells were 
lysed using ACK lysis buffer (Quality Biological, cat. 118-156-721). The resulting 
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single-cell suspensions were used for subsequent isolation of specific immune cell types 
or flow cytometry as described below. Blood from neu-N mice was obtained via retro-
orbital bleeds as per protocol. Red blood cells were lysed using ACK lysis buffer 
(Quality Biological, cat. 118-156-721). Isolated cells were analyzed via flow cytometry. 
To obtain single-cell suspensions of livers containing metastases in the PDAC model, 
livers were harvested and processed by mashing the liver through 100 µm and 40 µm cell 
strainers as previously described (50). Red blood cells were lysed using ACK lysis buffer 
(Quality Biological, cat. 118-156-721) and liver pellets were resuspended in 40% Percoll 
(GE Healthcare Life Sciences, cat. 17-0891-01) and underlayed with 80% Percoll. The 
immune cell layer was then removed and analyzed via flow cytometry.  
 
Immune cell isolation 
G-MDSCs were isolated from single-cell suspensions from tumors following tumor 
dissociation using Miltenyi Biotec’s Myeloid-Derived Suppressor Cell Isolation Kit (cat. 
130-094-538) according to the manufacturer’s protocol. Ly6G+ cells were positively 
selected to isolate G-MDSCs from Ly6G- M-MDSCs and were passed through LS 
columns (Miltenyi Biotec, cat. 130-042-401) twice to increase purity. Eluted G-MDSCs 
were then used for downstream assays described below. CD8+ T cells were negatively 
isolated from spleens of Balb/c mice above by mashing spleens through 100 µm cell 
strainers. Red blood cells were lysed using ACK lysis buffer (Quality Biological, cat. 
118-156-721), and CD8+ T cells were isolated from spleen pellets using the EasySep 
Mouse CD8+ Isolation Kit (StemCell, cat. 19853) per the manufacturer’s instructions. 
CD8+ T cells were then used for the in vitro suppression assay described below. 
 
 77 
Flow cytometry  
Isolated single-cell suspensions were washed and then incubated for 30 minutes with 
Live/Dead Near-IR (ThermoFisher, cat. L10119) according to the manufacturer’s 
protocol, followed by a 30-minute incubation with the appropriate flow cytometry 
antibodies. Samples were run on a CytoFLEX (Beckman Coulter) cytometer and 
analyzed using FlowJo (FlowJo LLC). 
 
Ex vivo G-MDSC culturing 
For ex vivo experiments using intratumoral G-MDSCs, G-MDSCs were plated in tumor 
conditioned media after being isolated as described above. Tumor conditioned media is 
derived by culturing NT2.5 for 48 hours in the NT2.5 media described above and 
subsequent filtering to remove tumor cells. 
 
Arginase assay 
Arginase activity was measured colorimetrically using Abcam’s Arginase Activity Assay 
Kit (cat. ab180877). For ex vivo studies, G-MDSCs were isolated from tumors, plated in 
tumor conditioned media with ENT or DMSO vehicle for 16 hours, and subsequently 
harvested. For in vitro studies, J774M were cultured with ENT or DMSO vehicle for 16 
hours and subsequently harvested. In short, cells were lysed with the kit’s lysis buffer at 
1x106/1mL, and plated (500k cells per well) in duplicate in a flat-bottom, low-retention 
plate carefully to avoid bubble formation. Target samples were incubated for 20 minutes 
at 37°C with H2O2 substrate solution, while background wells were incubated with 
additional buffer. Standards were prepared per kit instructions, and the enzymatic 
reaction mixture was prepared and added to all wells. Raw absorbance values were 
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immediately obtained over a 30-minute period using a plate reader (Molecular Devices 
SpectraMax M3) at OD=570nm at 37°C. Arginase Activity Units were then calculated 
from raw absorbance values. ΔOD (ΔOD= (OD2-ODbg2)-(OD1-ODbg1)) was used to 
obtain the nmol of H2O2 generated by arginase, collected from a standard curve of known 
H2O2 concentrations. Arginase activity is calculated as (B/ΔT*V)*D in units/mL, where 
B is amount of H2O2 from standard curve (nmol), V is the sample volume added into 
reaction well (µL), D is sample dilution factor. One unit of Arginase activity refers to the 
amount of arginase that will generate 1.0 nmol of H2O2 per minute at pH 8 at 37°C. 
 
In vitro suppression assay 
J774M cells treated with ENT or DMSO vehicle for 16 hours were co-cultured with 
stimulated T cells. T cell proliferation was measured via CFSE dilution. T cells were 
isolated from spleens of Balb/c mice as described above and subsequently labeled with 
CFSE (ThermoFisher, cat. C34554) per the manufacturer’s insstructions. 2.5 x105 CSFE-
labeled CD8+ T cells were cultured with J774M cells at varying ratios (1:1 – 1:8 
J774M:T cells) and anti-CD3/CD28 beads (ThermoFisher, cat. 11453D) at a bead-to-T 
cell ratio of 1:1 per the manufacturer’s instructions for T cell activation. T cells were 
allowed to proliferate for 52 hours. Subsequently, the cultures were harvested, stained 
with Live/Dead NIR (ThermoFisher, cat. L10119) as well as CD8 and analyzed via flow 
cytometric analysis as described above. Dilutions of initial CFSE were indications of T 
cell divisions, where fewer divisions indicated greater suppressive activity. All antibodies 




PDAC hemi-splenectomy in vivo studies 
To study metastatic PDAC, we used a hemi-splenectomy model using 7-8 week old 
syngeneic male C57BL/6J. This involved giving an intrasplenic injection of 2x106 of the 
pancreatic adenocarcinoma cell line (Panc02), as previously described (44–46). Panc02 
cells were cultured from frozen stocks and passaged twice before injection. Metastases 
were allowed to establish for 7 days prior to starting treatment with various drug 
combinations as described in Chapter 1. 
 
Western blots 
For analysis of in vivo samples, G-MDSCs were isolated from whole tumor of treated 
animals using Miltenyi Biotec’s MDSC Isolation Kit and pooled by treatment group. For 
ex vivo samples, G-MDSCs were isolated from untreated animals, cultured with ENT or 
DMSO vehicle in tumor conditioned media for 16 hours as described above, and 
subsequently harvested. For in vitro analysis, J774M cells were cultured with ENT or 
DMSO vehicle for 16 hours and subsequently harvested. Samples being used for 
phospho-STAT3 analysis were subsequently stimulated with IL-6 at 20 ng/μl for 25 
minutes. Samples were lysed in RIPA buffer with added 1μM DTT, 1μM PMSF, and 
1:100 protease/phosphatase inhibitor cocktail (Cell Signaling #5872S) and quantified by 
BCA (Pierce, #23225). Protein amounts were normalized between samples and run on a 
4-12% Bis-Tris gels under denaturing conditions. The LiCor Odyssey developing and 
imaging system was used, and the following primary antibodies were diluted in Odyssey 
Blocking Buffer (TBS) + 0.2% Tween® 20 at specified concentrations: Cell Signaling 
Phospho-Stat3 (Tyr705) Rabbit mAb (1:2000), b-actin (13E5) Rabbit mAb (1:2000). 
Membranes were blocked with Odyssey blocking buffer TBS for 1hr and then incubated 
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with primary antibody solution overnight at 4°C with gentle shaking. Membranes were 
washed with 1X TBS-T and subsequently incubated with the following secondary 
antibodies: 800CW Donkey anti-Rabbit IgG (1:10,000) in Odyssey Blocking Buffer 
(TBS) + 0.2% Tween® 20. Membranes were protected from light during incubation with 
secondary mixture for one hour at room temperature with gentle shaking. Membranes 
were subsequently washed with 1X TBS-T and imaged with the Odyssey® imaging 
system. Images were analyzed using ImageJ. 
 
Statistical analyses 
For bar graphs, each dot represents a biological replicates and each bar represents mean ± 
SEM. (n = 2-3 replicates/group). For Western blot and arginase activity data, significance 
was determined by a one-way ANOVA with Tukey’s multiple comparisons test. All 
experiments were repeated at least 3 times. For immunosuppression data, significance 
was determined by a two-way ANOVA with Dunnett’s multiple comparison’s test. All 
statistical analysis listed here were performed using GraphPad Prism v7.00. Statistically 





J774M cells phenotypically resemble intratumoral MDSCs 
 We hypothesized that ENT could be reprogramming MDSCs by altering STAT3 
activity and subsequent expression of key immunosuppressive genes regulated by 
STAT3. In order to perform the ChIP-Seq experiment to evaluate this hypothesis, we 
aimed to validate the J774M cell line (kindly provided by Dr. Kebin Liu) as a model for 
MDSC immunosuppression. The J774M cell line has previously been described as an 
MDSC-like cell line, expressing similar surface markers to those expressed by tumor-
induced MDSCs in mice. These cells also express various immunosuppressive molecules, 
allowing them to suppress T cell proliferation in a manner similar to intratumoral MDSCs 
(30,80,81). We performed flow cytometric analysis and found the J774M cells to be 
almost exclusively CD11b+ Gr1+, as previously described (80). Additionally, we found 
the cells to express both of the classic murine MDSC markers Ly6C and Ly6G (Fig. 1a), 
showing that the surface marker expression of the J774M line resembles that of 
intratumoral MDSCs. 
 
ENT inhibits Arg-1 production in both J774M cells and ex vivo G-MDSCs  
 Next we wanted to determine if J774M cells were capable of producing functional 
Arg-1, a key protein in MDSC-mediated T cell suppression, and if treatment with ENT 
could disrupt Arg-1 production as we observed in vivo. To determine this, we utilized a 
colorimetric assay to determine Arg-1 activity, which is defined by the conversion rate of 
Arg-1 substrate. These data show that J774M cells are not only capable of producing 
active Arg-1 protein, but treatment with ENT decreases the levels of Arg-1 production, 
similar to our in vivo observations (Fig. 2a). This in part supports the use of the J774M 
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line as a model of MDSC immunosuppression, as Arg-1 has previously been described as 
playing a key role in MDSC-mediated T cell suppression (24,30,82). Additionally, we 
confirm these findings in intratumoral G-MDSCs isolated from tumors of untreated neuN 
mice and cultured with ENT ex vivo (Fig. 2b). This decrease in Arg-1 production in ex 
vivo G-MDSCs treated with ENT supports the findings of our in vivo studies, where ENT 
drives MDSC dysfunction while ICIs drive T cell infiltration in combination treated 
































Figure 1: Flow cytometry characterization of the J774M cell line. (a) Flow staining of 














































Figure 2: ENT inhibits arginase production in both J774M cells and ex vivo G-
MDSCs. (a) J774M cells were harvested after 16 hours of treatment with ENT and 
arginase activity was measured. Each dot represents one biological replicate and each bar 
represents mean±SEM. (b) Ly6G+ G-MDSCs were isolated from tumors of untreated 
neuN mice. G-MDSCs were treated with ENT ex vivo for 16 hours in tumor conditioned 
media, harvested, and arginase activity was measured. Each dot represents G-MDSCs 
pooled from two tumors and each bar represents mean±SEM. All experiments were 
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 85 
 
J774M immunosuppressive functions can be inhibited by ENT 
 Our previous ex vivo immunosuppression studies in neuN mice showed a 
significant decrease in the immunosuppressive functions of intratumoral G-MDSCs 
isolated from ENT-treated animals compared to G-MDSCs isolated from vehicle treated 
animals. Therefore, we wanted to validate that the J774M line was capable of suppressing 
T cell proliferation. We also wanted to determine if any observed T cell suppression 
could be inhibited by ENT treatment. J774M cells were pre-treated with DMSO vehicle 
and subsequently co-cultured with CFSE-labeled CD8+ T cells isolated from Balb/c 
splenocytes at varying dilutions. T cells were then activated via stimulation with anti-
CD3/CD28 beads. T cells were allowed to proliferate for 52 hours, harvested, and 
analyzed via flow cytometry. We found that J774M cells were able to suppress T cell 
proliferation in a dose-dependent fashion (Fig. 3a, 3b). When J774M were pre-treated 
with either 0.5 µM or 1 µM ENT, their ability to suppress T cell proliferation was 
significantly impaired compared to the DMSO vehicle control (Fig. 3a, 3b), which aligns 
with what we observed in intratumoral G-MDSCs isolated from ENT-treated animals. 
These results further support the use of the J774M line as a model for MDSC 
immunosuppression, as these cells not only inhibit T cell proliferation but also respond to 















Figure 3: ENT inhibits J774M-mediated suppression of CD8+ T cell proliferation. 
J774M cells were treated with treated with ENT for 16 hours and co-cultured with CFSE-
labeled CD8+ T cells isolated from spleens of Balb/c mice. Anti-CD3/CD28 beads were 
added to the cultures to induce T cell stimulation and T cells were allowed to proliferate 
for 52 hours. The “stim control” culture contained only CFSE-labeled CD8+ T cells and 
anti-CD3/CD28 beads. Cultures were harvested and analyzed via flow cytometry. (a) 
CFSE peaks of live CD8+ T cells. Each peak represents a cell division as determined by 
CFSE dilution  (b) Quantification of percentages of proliferating CD8+ T cells with each 
treatment group compared to the DMSO control. n = 2 replicates per group. Each bar 
represents mean±SEM. Each experiment was repeated at least 3 times. Statistically 
significant p values are abbreviated as follows: ***p<0.001, ****p<0.0001. 








































ENT inhibits IL6-induced STAT3 phosphorylation 
 In our neuN in vivo studies, we observed a decrease in signaling of various 
pathways that converge at STAT3 and confirmed that IL6-induced phosphorylation of 
STAT3 was decreased in intratumoral G-MDSCs isolated from treated animals. This 
decrease in IL6-induced phosphorylation of STAT3 in ENT-treated intratumoral G-
MDSCs was further confirmed in our Panc02 hemisplenectomy model (Fig. 4c). Once we 
determined that the ENT treatment prevented J774M cells from producing Arg-1 and 
suppressing T cell proliferation, we next wanted to evaluate how ENT altered IL6-
induced phosphorylation of STAT3 in the J774M line. We treated J774M cells with ENT, 
stimulated STAT3 phosphorylation with IL6, and lysed cells. When probing the lysate for 
phospho-STAT3, we found a significant decrease in phospho-STAT3 in cells treated with 
ENT (Fig. 4a, 4b), which is comparable to what we observed in both our in vivo neuN 
and Panc02 studies (Ch. 1: Fig. 1b-d, Supplementary Fig. 4b, 4c). These data indicate that 





























Figure 4: ENT inhibits IL6-induced phosphorylation of both J774M cells and 
isolated intratumoral G-MDSCs from treated Panc02 mice.  J774M cells were 
stimulated with IL6 and lysed. (a) Western blot of lysates probed for phospho-STAT3 
and beta-actin. (b) Quantification of pSTAT3 bands normalized to vehicle (n = 2 
biological replicates/group). Intratumoral G-MDSCs isolated from livers of treated 
animals, stimulated with IL6 and lysed. (c) Representative quantification of  pSTAT3 
bands normalized to vehicle. All experiments were repeated at least twice. Statistically 































































































































J774M In vivo G-MDSCs 
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Discussion 
 We demonstrated that the surface marker expression and function of the J774M 
line resembles that of intraturmoral MDSCs, where J774M cells express CD11b, Gr1, 
Ly6G, and Ly6C as well as produce functional Arg-1 and inhibit T cell proliferation in a 
dose-dependent fashion. Additionally, we evaluated ENT’s effect on these 
immunosuppressive functions and found that ENT treatment significantly impairs the 
ability of J774M cells to produce Arg-1 and suppress T cell proliferation. These data 
resemble what we have observed in both intratumoral MDSCs isolated from treated 
animals as well as isolated intratumoral G-MDSCs cultured and treated ex vivo with 
ENT. In our in vivo work, ENT-induced MDSC dysfunction was associated with a 
decrease in STAT3 phosphorylation. We also evaluated the effect of ENT treatment on 
STAT3 activity in the J774M line and found that ENT treated cells had a significant 
decrease in IL6-induced STAT3 phosphorylation. Taken together, these data suggest that 
the J774M line is a good model for studying the role STAT3 in ENT-mediated MDSC 
reprogramming. 
 Our data not only validate use of the J774M line for our future mechanistic 
studies, but they also confirm the work of others using this cell line to model MDSC 
biology. Specifically, these data support previous observations that the J774M line is 
capable of suppressing T cell proliferation (30,80,81). Additionally, our data are in line 
with the findings of Orillion et. al, which show that treatment of J774M cells with 
entinotat can decrease Arg-1 expression and inhibit T cell immunosuppression (30). This 
work also shows an increase in STAT3 acetylation when J774M cells are treated with 
ENT. We add to this work by showing ENT treatment of J774M cells results in a direct 
decrease in STAT3 phosphorylation. 
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These data lay the foundation for future studies to further investigate the role of 
STAT3 in MDSC biology and in MDSC immunosuppressive dysfunction induced by 
ENT. Our studies with the J774M line will focus on validating the role of STAT3 in 
J774M immunosuppression in addition to mechanistically understanding the effect of 
ENT on STAT3 promoter binding and subsequent transcriptional events. We hypothesize 
that ENT treatment prevents phosphorylation of STAT3 and subsequently prevents 
STAT3 binding to the promoters of genes essential to MDSC immunosuppressive 
function. We are currently working to further validate the role of STAT3 in MDSC 
immunosuppression using the antisense oligonucleotide STAT3 inhibitor AZD9150. By 
performing the same arginase production and immunosuppression assays described above 
with the J774M line and intratumoral MDSCs cultured ex vivo. We will determine if 
specific STAT3 inhibition results in the same immunosuppressive dysfunction that is 
observed with ENT treatment.  
Our current work is also focused on optimizing and performing ChIP-Seq for 
phospho-STAT3. Our goal is to compare differences in phospho-STAT3 promoter 
binding between J774M cells untreated and treated with ENT. With the data obtained 
from this experiment, we hope to identify a number of genes that ENT treatment alters 
the binding of STAT3 to their promoters. Once affected genes have been identified, we 
will determine if knockout or knockdown of these genes in the J774M cells is sufficient 
to cause immunosuppressive dysfunction. Additionally, we aim to determine if ENT 
treatment is directly impeding transcription by performing ChIP-Seq on RNA polymerase 
II and evaluating changes in binding of transcriptional machinery at genes of interest. 
These data will not only further elucidate the role of STAT3 in MDSC biology but also 
identify new, more specific targets for MDSC reprogramming. Once we have identified 
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changes in STAT3 promoter binding in the J774M line, we will validate these changes in 
vivo by performing ChIP-PCR on intratumoral MDSCs treated with ENT. Once 
validated, we will knockout the selected genes in the J774M line via CRISPR and 
evaluate changes in immunosuppressive function via arginase activity and 
immunosuppression assays. This will identify the knockout lines with the greatest 
decrease in immunosuppressive functions. We will then adoptively transfer the most 
dysfunctional J774M knockout lines as well as wild-type J774M cells into the syngeneic 
4T1 breast cancer model with endogenous MDSCs depleted using an anti-Gr1 antibody. 
We will subsequently evaluate the effect of dysfunctional J774M cells versus wild-type 
J774M cells on tumor growth and survival. We will further investigate how deletion of 
immunosuppressive genes of interest in our MDSC-like J774M line impacts immune 




O V E R A L L   S U M M A R Y 
In summary, our data demonstrated ENT sensitizes non-immunogenic breast and 
pancreatic tumors to ICI therapy by reprogramming intratumoral MDSCs, rendering them 
unable to produce immunosuppressive factors and suppress T cell proliferation. Gene 
profiling and immunoblot analysis suggested this dysfunction is driven by a decrease in 
STAT3 activity in MDSCs. We further validated this hypothesis using the MDSC-like 
cell line J774M, showing that ENT treatment of J774M cells inhibits their ability to 
generate Arg-1 and suppress T cell proliferation, which correlated with a decrease 
STAT3 activity. 
In our murine models of breast and pancreatic cancer, we show that combining 
the histone deacetylase inhibitor ENT with the ICIs, anti-PD-1 and anti-CTLA-4, 
significantly improve survival in murine models of breast and pancreatic cancer. By 
utilizing flow cytometry and ex vivo functional assays, we found this improved survival is 
correlated with decreased immunosuppressive capabilities of intratumoral G-MDSCs in 
both models. Additionally, we demonstrated that combination therapy increases the 
infiltration of effector cytotoxic T cells in the TME in both models. Genetic profiling of 
both isolated intratumoral G-MDSCs as well as whole TIL found significant changes in 
immune-related pathways. Specifically, intratumoral G-MDSCs from treated animals 
showed changes in various signaling pathways that converge at STAT3. We confirmed a 
decrease in STAT3 phosphorylation in treated G-MDSCs, which suggested changes in 
STAT3 activity may be driving ENT reprogramming of intratumoral MDSCs.  
We next validated the MDSC-like cell line J774M in order to perform 
mechanistic studies designed to detail how ENT treatment alters STAT3 binding activity. 
We found J774M cells phenotypically resemble intratumoral MDSCs via flow cytometry. 
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Using arginase production and T cell proliferation assays, we also found the J774M line 
produced similar immunosuppressive factors and suppressed T cell proliferation as 
observed in intratumoral MDSCs. We also show ENT inhibits these immunosuppressive 
qualities of the J774M line, which is correlated with a decrease in STAT3 
phosphorylation. Taken together, these data show that ENT is able to inhibit MDSC 
immunosuppressive function and sensitize non-immunogenic breast and pancreatic 
cancers to ICI therapy. Furthermore, data from both intratumoral MDSCs and the MDSC-
like J774M line suggest this reprogramming of MDSC function is driven by changes in 
STAT3 activity. Additionally, our characterization of the J774M line demonstrates it is a 
good model for MDSC suppression and ENT-induced MDSC dysfunction, validating the 
use of this cell line for our STAT3-ChIP experiment and subsequent mechanistic studies.  
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